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IL-17 is a proinflammatory cytokine that mediates host defense against extracellular pathogens 
but also contributes to the pathogenesis of various autoimmune diseases, such as rheumatoid 
arthritis, multiple sclerosis and psoriasis. Despite some homology with the toll-like receptors, IL-
17 receptor subunits (IL-17RA and IL-17RC) do not recruit adaptors such as MyD88, but instead 
associate with and signal through the E3 ubiquitin ligase Act1. Upon recruitment, Act1 
ubiquitinates tumor necrosis factor receptor associated factor 6 (TRAF6), resulting in the 
activation of downstream transcription factors, nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), CCAAT-enhancer binding proteins (C/EBPs) and mitogen-activated 
protein kinases (MAPKs). Despite advances in our understanding IL-17 signaling, the details of 
molecular events involved in negative regulation of IL-17 signaling still remain unclear. 
Therefore, we focused our attention on feedback inhibitory mechanisms mediated by proteins 
that are regulated by IL-17. Here we describe three novel inhibitors of IL-17 signal transduction, 
A20, anaphase promoting complex subunit 5 (AnapC5) and monocyte chemotactic protein 1 
induced protein 1 (MCPIP1). We uncovered non-overlapping function of these proteins in IL-17 
pathway, signifying their importance in inhibiting inflammatory signaling. A20 is a 
deubiquitinating enzyme that restricts IL-17-induced TRAF6 ubiquitination, whereas AnapC5 
associates with A20 and appears to function as an adaptor protein in the A20/IL-17 pathway. 
MCPIP1, on the other hand, is an RNase that degrades Il17ra and Il17rc mRNA, thereby 
restraining IL-17 signaling. Notably, gene expression of A20 and MCPIP1 is regulated by IL-17, 
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indicating feedback inhibition of IL-17 signaling pathway. In summary, our findings have 
advanced the understanding of IL-17 signaling inhibition, may provide a novel mechanistic 
approach for controlling IL-17-induced inflammation and ultimately treating IL-17 mediated 
autoimmune diseases. 
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1.0  CHAPTER ONE: INTRODUCTION 
1.1 INFLAMMATION AND CYTOKINES 
Over five decades ago, the discovery of soluble factors (Interferons, IFN) that confer protection 
against viral infections laid the foundation of cytokine research [1, 2]. Since then, numerous 
cytokines have been identified that are central players in a variety of immune functions, ranging 
from development of immune cells to counteracting infections (reviewed in [3, 4]). 
One domain where the role of cytokines has been appreciated for a long time is the 
regulation of inflammation. Cytokines such as tumor necrosis factor-α (TNFα), granulocyte–
macrophage colony-stimulating factor (GM-CSF), interleukin-1 (IL-1) and IL-6 have been 
recognized to affect the local tissue environment and recruitment of inflammatory cells [5-8]. 
Through these functions, cytokines contribute to host defense by helping the immune system 
control and eliminate pathogens. Conversely, chronic inflammation by these cytokines leads to 
several autoimmune conditions and can be detrimental to the host. Indeed, the neutralization of 
inflammatory cytokines by antibodies is one of the most effective treatments for autoimmunity 
(reviewed in [9]). This is clearly evident by the success of TNFα neutralizing antibodies in the 
treatment of rheumatoid arthritis [10]. However, lack of these cytokines can lead to an enhanced 
susceptibility to pathogens. For example, pateints undergoing anti-TNFα therapy are more 
susceptible to mycobacterial infections such as reactivated tuberculosis [11]. Moreover, 
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cytokine neutralization therapies are not successful in all patients. Therefore, it is essential to 
identify and study additional cytokine targets that can complement existing therapies. 
Additonally, it may be possible to minimize the side effects of cytokine neutralization by 
identifying specific mechanisms of targeting cytokine activity without losing the beneficial 
functions.  
In this regard, the Gaffen laboratory focuses on the novel IL-17 cytokine family. IL-17A 
(commonly referred to as IL-17) is the signature cytokine of this family and has been associated 
with the development of several autoimmune diseases. Compared to previously identified 
cytokine families, the IL-17 family is unique in several aspects that will be explained in the 
following sections of this introduction, as well as in subsequent chapters in this thesis. 
1.2 IL-17 FAMILY AND TH17 CELLS 
Interleukin 17 was cloned from a subtractive rodent cDNA library and initially named CTLA8 
[12]. Initial homology studies predicted that IL-17 lacked significant resemblance to existing 
cytokines, but shared approximately 57% homology to the ORF13 of Herpesvirus saimiri 
(HVS). Other IL-17 family members were identified on the basis of homology to IL-17A and 
the IL-17 family is currently composed of six cytokines (IL-17A through IL-17F) [13, 14]. 
Among the IL-17 family members, IL-17F was the first cytokine that was crystalized [15]. 
Although distinct in primary sequence, IL-17F was found to be structurally similar to cysteine 
knot cytokines such as platelet-derived growth factor (PDGF) and nerve growth factor (NGF).  
Furthermore, crystal structure and computer models confirm that IL-17 adopts a similar three-
dimensional conformation [16]. 
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Another group cloned the IL-17 receptor (IL-17R, now known as IL-17RA) by 
screening an EL4 cDNA expression library with an HVS13.Fc fusion protein [17]. Similar to its 
ligand IL-17, IL-17RA did not share detectable homology with other cytokine receptors. 
Likewise, four other members of the receptor family (IL-17RB to IL-17RE) were discovered on 
the basis of homology to IL-17RA [18]. While the lack of apparent homology of IL-17 and IL-
17 receptor to other existing cytokine families made it challenging to predict the function of IL-
17, this lack of homology simultaneously raised the prospect of a novel class of proteins that 
could help explain poorly understood immune activities. 
Initial reports suggested that CD4+ T cells are the primary source of IL-17 [13, 19]. 
However, it took nearly a decade after the cloning of IL-17 to determine the nature of IL-17 
producing cells. In 2005, reports from several groups defined a distinct subset of T helper (TH) 
cells that produce IL-17 as their signature cytokine [20-22]. Based on IL-17 production by these 
cells, the term ‘TH17’ was coined. 
Several seminal reports in quick succession established the phenotype and function of 
TH17 cells. In addition to IL-17, TH17 cells produce the related family member IL-17F, as well 
as other cytokines such as IL-21 and IL-22. TH17 cells require a combination of cytokines to 
develop and mature, including IL-6, transformation growth factor (TGF)-beta (TGF-β), IL-1β 
and IL-23. IL-23 shares a common subunit with IL-12, which in IL-23 pairs with a distinct 
subunit, p19 (reviewed in detail elsewhere [23]). The transcription factors important for the 
development of TH17 cells also differ from TH1 and TH2 cells. Specifically, TH17 cells require 
the activation of RAR-related orphan receptor gamma (RORγt) and signal transducer and 
activator of transcription 3 (STAT3) for maturation, as opposed to T-box transcription factor 
TBX21 (Tbet) for TH1 and GATA-binding factor 3 (GATA3) for TH2 cells [24, 25]. 
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Initial studies suggested that TH17 cells drive autoimmune inflammation. Multiple 
autoimmune mouse models were used to prove that TH17 cells (not TH1 cells) are the primary 
drivers of autoimmunity through their production of IL-17. These models include experimental 
autoimmune encephalomyelitis [(EAE), mouse model of multiple sclerosis] [20] and collagen 
induced arthritis [(CIA), mouse model of arthritis] [26]. Subsequently, the role of IL-17 has 
been described in several autoimmune conditions, indicating that TH17 cells are critical drivers 
of autoimmunity [27]. TH17 cells and IL-17-producing cells are not only associated with 
autoimmune conditions but also help control infections by extracellular bacteria and fungi. For 
example, deficiency in IL-17 production or its function has been shown to increase 
susceptibility to Klebsiella pneumoniae and Candida albicans infections [28, 29]. 
While much of the early focus was on IL-17 production from TH17 cells, there is a 
significant body of evidence to suggest that there are other lymphocyte populations that serve as 
"innate" sources of IL-17. These cells include γδT cells, LTi-like cells, natural TH17 and innate 
lymphoid cells (ILC, especially the ILC3 subset) [30]. These cells appear to function primarily 
in a defensive capacity against pathogens at mucosal surfaces, providing an early source of IL-
17 to recruit neutrophils to sites of infection. In addition, these innate IL-17 producers have 
been shown to participate in the initiation of certain autoimmune diseases. Further 
characterization of these cell types will shed more light on their respective contribution in the 
production of IL-17 and disease pathology. 
The genes induced by IL-17 help explain its pro-inflammatory activities (reviewed in 
[31]). Chemokines regulated by IL-17 such as chemokine (C-X-C motif) ligand 1 (CXCL1), 
CXCL2 and CXCL5 promote neutrophil chemotaxis. IL-6 and granulocyte-colony stimulating 
factor (G-CSF) regulate the survival, proliferation and recruitment of myeloid lineages, 
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especially neutrophils. IL-17 also induces expression of CCL20, which promotes trafficking of 
mucosal-associated cells bearing the chemokine receptor CCR6; notably, CCR6 is a 
characteristic receptor on IL-17-expressing cells such as TH17 cells and ILC3s [32]. 
Additionally, IL-17 is a strong inducer of antimicrobial peptides (AMPs), particularly β-
defensins, which play vital roles at mucosal surfaces and skin in preventing infection, and which 
may also exert chemotactic activity. Lipocalin-2 is another antimicrobial protein induced by IL-
17 that controls bacterial growth by restricting access to dietary iron. The majority of the 
inflammatory genes mentioned here are not exclusively IL-17 targets, but are also induced by 
other proinflammatory stimuli such as TNFα, lipopolysaccharide (LPS) and IL-1β. In fact, IL-
17 synergizes with these proinflammatory proteins to further enhance its target gene expression 
[18, 31, 33]. Furthermore, the similarities of IL-17 induced gene expression to LPS/IL-1β have 
led to valuable insights into the in vivo role of IL-17 as well as signaling components of the IL-
17 pathway. 
Other IL-17 family members studied to date include IL-17E (IL-25) and IL-17C. 
Compared to IL-17, these cytokines have distinct activities and use other IL-17 receptor family 
members for signaling. IL-17E and IL-17C signal through IL-17RB and IL-17RE, respectively 
[34]. Intriguingly, both IL-17E and IL-17C use IL-17RA in addition to IL-17RB and IL-17RE, 
indicating that IL-17RA may be a shared receptor subunit for the IL-17 family cytokines. 
Therefore, at least some mechanisms of regulation dependent on IL-17RA are presumably 
applicable to IL-17E and IL-17C. However, a detailed discussion of IL-17C and IL-17E biology 
is outside the scope of this thesis [35-37]. 
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1.3 IL-17: PARTNER IN HEALTH AND DISEASE 
IL-17 is the hallmark cytokine of TH17 cells and contributes to the inflammatory impact of these 
cells. As mentioned earlier, IL-17 exerts protective effects for the host in the context of host 
defense against pathogens whereas IL-17-induced autoimmune inflammation is detrimental for 
the host. The role of IL-17 in regulating different pathogens and autoimmune conditions will be 
described in this section. 
1.3.1 IL-17 and Autoimmunity 
Inflammation induced by IL-17 has been associated with several autoimmune conditions, 
including rheumatoid arthritis (RA), psoriasis, multiple sclerosis (MS), systemic lupus 
erythematosus (SLE), glomerulonephritis, ankylosing spondylitis, Crohn’s disease and multiple 
lung disorders (reviewed in [38]). The role of IL-17 and IL-17R in the development of these 
autoimmune diseases has been confirmed in mouse models of some of these diseases [20, 22, 
39-41]. Moreover, elevated levels of IL-17 have been detected in the serum of RA and psoriasis 
patients [42, 43]. In these autoimmune diseases, IL-17 targets tissue specific cells and activates 
inflammatory gene expression that ultimately drives the autoimmune phenotype. For example, 
in RA, IL-17 acts on synoviocytes by binding to its receptor, resulting in chronic inflammation 
of synovial tissues in multiple joints that has been associated with bone and cartilage damage 
[39, 44, 45]. Similarly, in EAE, IL-17 activates astrocytes and microglial cells to produce 
inflammatory cytokines and chemokines [46], aiding the recruitment of additional inflammatory 
innate and adaptive immune cells.  
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Finally, genome-wide association studies (GWAS) reported the IL-23 gene as a 
susceptibility locus in inflammatory bowel disease (IBD) [47]. As stated earlier, IL-23 drives 
the development and maintenance of TH17 cells, further emphasizing the role of TH17 cells in 
driving chronic autoimmune conditions. Unexpectedly, IL-17 and IL-17RA deficiency in T 
cells further exacerbated this disease, indicating a protective role for IL-17 in IBD [48, 49]. 
Interestingly, IL-17F was found to be pathogenic in this model and was shown to be the primary 
inducer of proinflammatory gene expression [50]. Cumulatively, these data indicate that IL-17 
is a critical driver of autoimmunity. 
1.3.2 Pathogen Control by IL-17 
Although IL-17 is notorious for its role in inducing autoimmunity, IL-17 did not evolve to cause 
autoimmunity, but rather to promote effective host defense against pathogenic insult. Thus, IL-
17- and IL-17R-knockout mouse models demonstrate increased susceptibility to a wide variety 
of infectious organisms, including gram-negative and gram-positive bacteria, parasites, fungi, 
and even some intracellular bacteria and viruses. 
The importance of the IL-17/TH17 axis in control of various pathogens is clearly evident 
in humans with mutations in genes along this axis. For example, patients with Job’s 
Syndrome/Hyper-IgE Syndrome (HIES) have autosomal dominant-negative mutations in 
STAT3 that are associated with dramatically reduced TH17 cell frequencies. These patients are 
susceptible to chronic mucocutaneous candidiasis (CMC, caused by the commensal fungus C. 
albicans), Staphylococcus aureus and Streptococcus pneumonia infections [51]. Similarly, 
mutations in STAT1 and caspase recruitment domain-containing protein 9 (CARD9) are also 
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associated with CMC and reduced TH17 cell numbers [52, 53]. Therefore, TH17/IL-17 
deficiencies are strongly linked to increased susceptibility to fungal and bacterial infections. 
1.3.3 IL-17 Neutralization for Autoimmune Treatment 
The association of IL‐17 and TH17 cells with a number of chronic inflammatory diseases makes 
this pathway a promising target of monoclonal antibody based therapy. Indeed, antibodies 
targeting IL-17 or IL-17R are currently being tested in several clinical trials. For example, A 
Phase-II clinical trial with an antibody targeting IL-17 (Secukinumab/AIN457, Novartis) 
exhibited a significant reduction in psoriatic lesions as compared to the placebo-treated group. 
This antibody also displayed moderate success in treating RA and uveitis [54]. The potential 
success of IL-17 neutralizing antibodies presents an exciting opportunity in the treatment of 
autoimmune conditions where TNFα blockers and other therapies have had limited efficacy. 
Also, as IL-17 synergizes with TNFα and other inflammatory cytokines, IL-17 targeting 
antibodies could potentially be used in combination with other cytokine therapies. Detailed 
discussion of these trials is beyond the focus of this introduction and has been reviewed in detail 
elsewhere [55]. 
A side effect of successful anti-cytokine therapies in the past has been an increase in 
susceptibility to infections. Whether targeting IL-17 also results in a similar outcome is yet to be 
determined, but early data indicates increased incidence of oral candidiasis in patients being 
treated with Secukinumab (unpublished data, presented by Dhavalkumar D. Patel, Novartis 
Institutes for BioMedical Research, Switzerland, at the Keystone Conference, Emerging 
Cytokine Networks, January 2014). Therefore, it is important to identify drug targets that reduce 
IL-17-induced inflammation sufficiently to treat autoimmunity but that do not compromise its 
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host defense activity. Clues about such proteins are abundant in nature where inflammation is 
kept in check by inhibitors of signal transduction such as phosphatases, ubiquitin ligases and 
deubiquitinases. Despite our increasing understanding of the physiological role of IL-17 and 
regulation of IL-17 production, the mechanisms of regulation of IL-17 triggered signaling 
cascades remain elusive. Therefore, the objective of this thesis is to identify and understand the 
mechanisms by which IL-17 signaling is kept in check. 
1.4 OVERVIEW OF IL-17 SIGNALING 
Initial attempts to understand IL-17 biology largely focused on the regulation of IL-17 
production and identification of the cells making IL-17 (TH17 and innate sources). However, 
compared to other inflammatory cytokines, very little is known about IL-17 signal transduction 
and regulation of this pathway. This section outlines our current understanding of the IL-17 
signaling pathway. 
1.4.1 IL-17 Signaling Activation 
IL-17 functions either as a homodimer or as a heterodimer with IL-17F [55]. Based on its 
induction of CXCL1, the IL-17A homodimer was found to be the most potent inducer of its 
target genes, followed by the IL-17A/F heterodimer, and finally the IL-17F homodimer [56].  
The effects of IL-17 (IL-17A, IL-17F and IL-17A/F) are mediated through a receptor 
complex composed of two IL-17 receptor family members, IL-17RA and IL-17RC [55]. Among 
IL-17R family members, IL-17RA has the longest cytoplasmic region (521 amino acids, murine 
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IL-17RA), suggesting that IL-17RA is likely to be important in recruiting receptor proximal 
adaptor proteins. On the other hand, IL-17RC has a shorter cytoplasmic domain (214 amino 
acids, murine IL-17RC). Generation of IL-17RA and IL-17RC knockout mice and subsequent 
analysis of IL-17 signaling in these mice confirmed the importance of both subunits in the 
activation of IL-17 signaling. Furthermore, structure-function analysis of IL-17RA and IL-
17RC demonstrated that the cytoplasmic domains of both receptor subunits are necessary for 
IL-17 signaling [33, 57-59]. 
The expression patterns of IL-17RA and IL-17RC are very different and determine the 
cell types that respond to IL-17. IL-17RA is expressed constitutively by most cell types 
including hematopoietic and non-hematopoietic cells. Conversely, IL-17RC is mainly expressed 
on non-hematopoietic cells. As IL-17RA and IL-17RC are both essential for IL-17 signal 
transduction, IL-17 is thought to mainly act on non-hematopoietic cells such as fibroblasts, 
synoviocytes, keratinocytes, epithelial and endothelial cells (reviewed in [34, 60]). These cells 
are also targets for other inflammatory cytokines like TNFα and contribute to tissue specific 
inflammation and autoimmunity. Thus, non-immune cells are pertinent tools for studying IL-17 
signaling pathways. 
IL-17R family members have considerable homology between their cytoplasmic 
domains but not to those of other receptor families, suggesting that the receptor proximal 
signaling events are unique to this family. The first insight into this pathway came from a 
landmark bioinformatics study that identified a conserved signaling motif among the IL-17 
receptor family. The domain was related to the toll-IL-1 receptor (TIR) domain of the toll-like 
receptor (TLR) and IL-1 receptor (IL-1R) family and was named SEFIR (after similar 
expression to the fibroblast growth factor receptor (SEF)/IL-17R) [61]. The same report 
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identified Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) activator 1 
(Act1), the only known protein outside the IL-17R family that has a SEFIR domain. At the time, 
Act1 (also known as CIKS (Connection to inhibitor of kappa light polypeptide gene enhancer in 
B-cells, kinase (IKK) and stress-activated protein kinase (SAPK)/ c-Jun N-Terminal Kinase 
(JNK)), had only been described as an activator of NF-κB and a negative regulator of cluster of 
differentiation 40 (CD40) and B cell activating factor belonging to the TNF family (BAFF) 
signaling in B cells [62-64]. The presence of a SEFIR domain in Act1 raised the interesting 
possibility that Act1 is an adaptor protein that regulates IL-17 signaling, similar to the function 
of myeloid differentiation primary response 88 (MyD88) in TLR/IL-1R signaling. Indeed, 
subsequent studies using RNA interference and Act1-/- mice confirmed that Act1 is essential for 
signal transduction by IL-17 as well as for other IL-17 family members [65-67]. Engagement of 
Act1 by the IL-17R (through a homotypic SEFIR-SEFIR interaction) leads to the activation of 
downstream signaling cascades. 
The primary function of Act1 is as an adaptor protein, linking IL-17 receptor to other 
activators of the pathway such as the TNF receptor associated factor (TRAF) family protein, 
TRAF6 [66, 68, 69]. Additionally, Act1 has enzymatic activity as an E3 ubiquitin ligase, and in 
that capacity mediates Lysine 63 (Lys-63 or K63) ubiquitination of TRAF6 [70] [Lys-63/K63 
ubiquitination described in Section 1.4.2]. Recruitment and ubiquitination of TRAF6 leads to 
the activation of TGF-β-activated kinase-1 (TAK1) and TAK1 binding proteins 2/3 (TAB2/3). 
TAK1 further activates the IKK complex, leading to activation of the canonical NF-κB pathway 
[18]. The Act1/TRAF6 axis is also important for the phosphorylation and activation of mitogen 
activated protein kinase (MAPK) pathways. Finally, Act1 appears to be essential for the 
overwhelming majority of IL-17-dependent signaling events. Therefore, it is not surprising that 
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the phenotypes of Act1-/- mice are similar to those of IL-17RA-/- mice. For example, like IL-
17RA-/- mice, Act1-/- mice are susceptible to C. albicans infection and have reduced severity of 
EAE as compared to wild-type (WT) mice [18, 46]. 
Heat shock protein 90 (Hsp90) also contributes to IL-17 signaling by regulating the 
function and stability of Act1. Lack of Hsp90 function results in proteasomal degradation of 
Act1, resulting in lack of IL-17 signaling. The D10N variant of Act1 (Act1-D10N) is defective 
in its interaction with Hsp90, which results in a global loss of Act1 function. Moreover, the 
Act1-D10N variant is linked to susceptibility to psoriasis, pointing to the physiological 
importance of Hsp90-Act1 association [71]. 
Another family of transcription factors, the CCAAT-enhancer-binding proteins 
(C/EBPs), is also involved in the regulation of IL-17 signal transduction. Two members of this 
family, C/EBPδ and C/EBPβ, are regulated by IL-17, albeit in different ways. C/EBPδ mRNA 
expression is induced by IL-17, whereas C/EBPβ is post-translationally modified (particularly 
by phosphorylation) as well as alternatively translated. C/EBP transcription factors cooperate 
with NF-κB to regulate IL-17-induced gene expression. Two examples of such genes are Il6 and 
lcn2 (lipocalin 2, also known as 24p3), which have both C/EBP and NF-κB sites in their 
promoters. Deletion of either site renders these promoters unresponsive to IL-17-mediated 
signals [72, 73]. 
As compared to TNFα and IL-1β, IL-17 and IL-17F are only modest activators of 
signaling on their own. However, IL-17 synergizes or cooperates with a variety of inflammatory 
effectors, particularly TNFα but also IFNγ, IL-22, lymphotoxin-beta (LT-β), IL-1β and LPS. 
This proves to be an important tool to study IL-17 signaling whenever IL-17 induced gene 
expression is too low or undetectable. More importantly, this is particularly relevant in 
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infections and autoimmune disorders, where IL-17 is induced in conjunction with other 
inflammatory proteins. The molecular basis for this synergy probably involves multiple 
mechanisms but to date remains poorly understood. In synovial tissue, IL-17 upregulates TNF 
receptor (TNFR) II expression, thereby enhancing responsiveness to TNFα signaling [74]. For 
some genes, cooperativity occurs at the level of the promoters (e.g., Il6 and lcn2) as both IL-17 
and TNFα activate transcription factors that bind to the promoters of these genes. IL-17 
upregulates expression of inhibitor of kappa light polypeptide gene enhancer in B-cells, zeta 
(IκBζ, a positively activating member of the IκB/NF-κB family), which in turn promotes 
expression of some IL-17 target genes [75]. 
In addition, IL-17 synergizes with TNFα by regulating mRNA stabilization of genes 
induced by TNFα. These genes encode chemokines such as cxcl1, chemokine (C-C motif) 
ligand 2 (ccl2) and csf3 (encodes G-CSF) [76-78]. Although Act1 is essential for IL-17-
regulated enhanced mRNA stability, TRAF6 is surprisingly dispensable. Regulation of the 
stability of these mRNAs occurs via inducible Act1 phosphorylation, mediated by IKKi (Ikkε) 
and TRAF family member-associated NF-κB activator (TANK) binding kinase 1 (TBK1) [79, 
80]. Phosphorylated Act1 binds to adaptors TRAF2 and TRAF5, which further recruit the 
splicing factor 2  (SF2) (also known as alternative splicing factor (ASF)). Sequestration of SF2 
via Act1/TRAF2/TRAF5 results in reduced SF2-mediated mRNA splicing activity and as a 
result, enhanced mRNA stability of cxcl1 mRNA [53, 79]. Furthermore, the 
Act1/TRAF2/TRAF5 axis promotes the recruitment of the mRNA stabilizing protein, HuR, to 
the cxcl1 and cxcl5 mRNA, resulting in enhanced mRNA stability [81]. IL-17 target mRNA 
regulation and synergy with TNFα is still not completely understood, but this is likely to be an 
important means by which inflammation is controlled by IL-17. 
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In conclusion, IL-17R plays an important role in the recruitment of early signaling 
activating proteins that regulate the downstream adaptor molecules as well as IL-17 target gene 
expression. Receptor structure-function analyses have demonstrated that, in addition to the IL-
17RA and IL-17RC SEFIR domains, extended domains beyond SEFIR are crucial in NF-κB, 
C/EBPβ and C/EBPδ induction. Moreover, the distal C-terminal domain of IL-17RA (CBAD) is 
important in C/EBPβ regulation, and thus, IL-17 target gene expression. Although our 
understanding of the IL-17 targets has increased tremendously, the IL-17R proximal events and 
their regulation are far from fully characterized.   
1.4.2 Ubiquitination and IL-17 Signaling 
Among the various regulatory mechanisms for modulating signaling pathways, post-
translational modifications of adaptor proteins are among the most important. One such 
modification is ubiquitination, in which ubiquitin (Ub) molecules are covalently linked to the 
target protein through specific lysine residues. A cascade of three proteins, E1 (ubiquitin-
activating), E2 (ubiquitin-conjugating) and E3 (ubiquitin ligase) are sequentially activated to 
carry out the ubiquitination (Figure 1.2). In most cases, the E3 ligase provides substrate 
specificity by directly binding and linking ubiquitin molecules to the substrate. The outcome for 
the target protein depends on the lysine residues of ubiquitin used to form these polyubiquitin 
chains. Of the seven Lysine (K) residues on ubiquitin, K48 and K63 are most commonly used to 
form polyubiquitin chains on proteins. K48-linked Ub targets substrate proteins to proteasomal 
degradation, whereas K63-linked Ub is important in mediating non-proteolytic functions such 
as protein-protein interactions and cell signaling events (reviewed elsewhere in [82-84]). 
Proteins such as TRAF6, TAB2, TAB3 and TAK1 have ubiquitin binding domains in their 
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structure that specifically bind to K63-linked ubiquitin chains. K63-linked ubiquitination of 
adaptor proteins is crucial in activating several inflammatory pathways. For example, 
ubiquitination of receptor (TNFRSF)-interacting serine-threonine kinase 1 (RIP1) and TRAF6 
in TNFα and TLR4/IL-1β signaling pathways, respectively, is central to the activation of 
downstream signaling cascades. Mutations of important residues targeted for ubiquitination on 
these adaptors render TNFα and TLR4/IL-1β signaling inactive. 
IL-17 signal transduction also involves ubiquitination as an important post-translational 
modification. Most of the known IL-17R proximal proteins are E3 ubiquitin ligases, which 
further underscores the importance of ubiquitination in IL-17R signaling. In fact, the E3 ligase 
activity of Act1 was recently reported to mediate K63 ubiquitination of TRAF6 [70], which is a 
critical event in IL-17R signaling. Upon ubiquitination, TRAF6 recruits TAK1 and activates the 
canonical NF-κB pathway. 
Conversely, removal of ubiquitin chains from adaptor proteins leads to the disruption of 
protein complexes and subsequent inactivation of inflammatory signaling (Figure 1.2). This 
process is carried out by enzymes known as ‘deubiquitinases’ (DUBs). The human genome is 
predicted to encode over 100 DUBs, but the identity and function of the vast majority of these is 
still unknown. A20 (TNFα induced protein 3, tnfaip3), CYLD (Cylindromatosis (Turban Tumor 
Syndrome)), A20 binding inhibitor of NF-κB (ABIN1) and several USP (Ubiquitin Specific 
Peptidases) proteins are some examples of deubiquitinase proteins that regulate inflammatory 
signaling pathways. The inhibition of inflammatory signaling by DUBs is essential to keep 
inflammation in check and to avoid any associated collateral damage. Furthermore, the 
importance of DUBs is well established by the association of gene loci encoding these 
deubiquitinases with susceptibility to several autoimmune conditions. For example, the human 
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A20 gene locus has been linked to susceptibility to Crohn’s disease, RA, SLE and psoriasis 
(reviewed in [85]) and human CYLD is a susceptibility locus in IBD [86-88]. The role of 
deubiquitination in regulating IL-17 induced inflammation is one of the main mechanisms 
discussed in this thesis and will be elaborated in detail in subsequent chapters (Chapters 3-4). 
1.4.3 IL-17 Signaling Inactivation 
Given the association of aberrant IL-17 production and signaling with the development of 
several autoimmune diseases, it is not surprising that there are multiple layers of restriction that 
control IL-17-mediated inflammatory signaling. A variety of inhibitory mechanisms have been 
identified (Figure 1.1). 
As mentioned, C/EBP proteins regulate IL-17-induced gene expression. Interestingly, 
C/EBPβ is both a positive and negative regulator of the IL-17 pathway. Although C/EBPβ can 
positively transactivate IL-17 target genes, C/EBP phosphorylation correlates with a decrease in 
IL-17-induced gene expression. Specifically, C/EBPβ is sequentially phosphorylated on two 
threonine (Thr) residues located within in the regulatory domain 2 (RD2) by the kinases 
extracellular signal-regulated kinases (Erk) and glycogen synthase kinase 3 beta (GSK-3β). 
Whereas ERK is activated via TRAF6 and the SEFIR domain of the IL-17RA, phosphorylation 
through GSK-3β is dependent on the IL-17RA distal C-terminal domain (hereafter mentioned as 
CBAD, C/EBPβ activation domain) [89].  
TRAF proteins also play both positive and negative roles in regulating the IL-17 
signaling pathway. TRAF6 is important for the activation of this signaling pathway. However, 
TRAF3 is a negative regulator of IL-17 signal transduction. TRAF3 inhibits IL-17 signaling by 
competing with Act1 for binding to IL-17RA, thereby dampening IL-17-dependent signals [90]. 
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TRAF3 also associates with IL-17RA through a consensus TRAF binding site in the CBAD 
domain of the receptor. CBAD-mediated recruitment of inhibitory proteins, GSK-3β and 
TRAF3, suggests a model where the IL-17RA CBAD is involved in the inhibition of IL-17 
signaling. Indeed, the deletion of the CBAD was linked to enhanced IL-17 signaling, 
confirming an inhibitory role of this domain. Receptors often function as docking sites for 
adaptors that activate inflammatory signaling pathways. Therefore, receptor-mediated 
recruitment of inhibitory proteins is an intriguing mechanism of limiting inflammation at the 
source. IL-17RA is the shared receptor for other IL-17 family cytokines, such as IL-17E and IL-
17C. Thus, these means of regulation could potentially be applicable to the other IL-17 family 
cytokine signaling pathways. Similar to TRAF3, TRAF4 directly binds Act1 upon IL-17 
stimulation and competes with TRAF6 for association with Act1 [91]. Consistently, TRAF3 and 
TRAF4 limit IL-17-mediated development of EAE. Taken together, these findings show that 
TRAF proteins are essential in the regulation of IL-17 signal transduction.  
Ubiquitination plays a vital role in a variety of proinflammatory cytokine signaling 
pathways, including IL-17, and a prolonged activation of these pathways leads to autoimmune 
disease. Thus, targeting ubiquitination as a mechanism for downregulating these pathways is a 
plausible strategy. Indeed, deubiquitination as a mechanism of inhibition was shown by a recent 
report describing a similar function of the DUB, USP25, which tempers IL-17-mediated signal 
transduction by targeting TRAF proteins. Here, USP25 removes K63-linked ubiquitin chains on 
both TRAF6 and TRAF5, resulting in inhibition of IL-17 target gene transcription as well IL-
17-induced mRNA stability. USP25 deficiency is associated with enhanced IL-17-dependent 
pulmonary inflammation and increased susceptibility to EAE [92]. The role of another DUB, 
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A20, and its accessory proteins in inhibiting IL-17 signaling is the focus of subsequent chapters 
and will be introduced later (Chapter 3-4). 
In contrast to K63-linked ubiquitination, K48-linked ubiquitination regulates 
inflammatory signaling by promoting the proteasomal degradation of proteins. For example, 
K48-linked ubiquitination of Inhibitor of κB alpha (IκBα) drives its degradation and permits 
nuclear import and activation of NF-κB. IκBα ubiquitination is carried out by the ubiquitin 
ligase complex, beta-transducin repeat containing E3 ubiquitin protein ligase (β-TrCP) [93-95]. 
β-TrCP also targets phosphorylated forms of Act1, leading to its degradation and loss of 
signaling [96]. 
These mechanisms suggest that post-translational modifications are vital for inhibition 
of IL-17 signaling. However, inhibition at the transcriptional level is also important in the 
negative regulation of this pathway. MicroRNAs (miR) have been implicated in regulating both 
TH17 development and IL-17 signaling. MiR-155, expressed in CD4+ T cells, positively 
regulates TH17 differentiation, which may be at least in part due to targeting of SOCS1 by 
miR155 [97]. Consequently, miR155-/- mice are susceptible to EAE. In terms of signaling, miR-
23b keeps IL-17-induced NF-κB activation in check by targeting the mRNA degradation of 
TAB2, TAB3 and IKKα. Consistently, patients with RA and SLE show reduced expression of 
miR-23b, which is regulated by IκBζ. Downregulation of miR-23b by IL-17 supports the role of 
IL-17 in the development of these autoimmune conditions [98].  
In addition to regulation by microRNA, adaptor mRNA transcripts as well as target gene 
mRNA can be targeted for degradation by RNases. These enzymes target the secondary 
structure of certain transcripts and lead to the degradation of mRNA. The activity and function 
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of an RNase, MCPIP1, in regulating IL-17 signaling will be introduced and expanded in this 
thesis (Chapter 5).  
1.5 SUMMARY 
Our fundamental understanding of IL-17-mediated functions in the immune system is 
increasing at a fast pace.  The importance of IL-17 is evident from the variety of innate and 
adaptive immune cells that produce this cytokine. It is equally essential to study the 
mechanisms by which IL-17 target gene expression is activated and inhibited. In this thesis, I 
report three proteins; (i) A20, (ii) Anaphase Promoting Complex subunit 5 (AnapC5), and (iii) 
Monocyte chemotactic protein (MCP-1) induced protein 1 (MCPIP1), that all function as 
negative regulators of IL-17 signaling. Although they have overlapping roles in inhibiting IL-17 
signaling, the mechanisms by which they act are completely different. A20 acts by 
deubiquitinating TRAF6, whereas the AnapC5/7 complex binds A20 and IL-17RA, thus 
potentially acting as a link between A20 and the receptor. Finally, MCPIP1 degrades Il17ra and 
Il17rc mRNA, thereby inhibiting IL-17 signaling. Taken together, findings in this thesis have 
greatly improved our understanding of IL-17 signaling inhibition as well as identified novel 
mechanisms of inflammatory signaling inhibition that can be applicable to other inflammatory 
pathways. 
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Figure 1.1: Schematic diagram of IL-17 signaling. 
Overview of IL-17 signaling pathway. Multiple proteins are involved in the activation and 
inhibition of IL-17 signaling and have been explained in detail in Chapter 1.  
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Figure 1.2: Ubiquitination and Deubiquitination. 
A cascade of enzymes sequentially act and link ubiquitin chains on the substrate in a process 
called ‘Ubiquitination’. Removal of these ubiquitin chains is referred to as ‘Deubiquitination’ 
and is carried out by a different class of enzymes,  
 
Note: This figure is reprinted with permission from Harbor Laboratory press. The original 
figure was published in the journal Cold Spring Harbor Perspectives in Biology 
2010;2:a003350, with copyright held by Cold Spring Harbor Laboratory Press [84].   
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2.0  MATERIALS AND METHODS 
  
 23 
2.1 MATERIALS 
2.1.1 Cell Culture and Reagents 
All cell lines were cultured in α-MEM (minimum essential medium, Sigma) containing 10% 
fetal bovine serum (FBS) supplemented with L-glutamine and antibiotics (Invitrogen), unless 
otherwise stated. Human FLS cells were cultured in α-MEM with 15% FBS, L-glutamine, and 
antibiotics. 
Plasmid transfection in Human Embryonic Kidney (HEK) 293T cells were carried out 
using the calcium phosphate method, whereas primary cells such as, A20−/− mouse embryonic 
fibroblasts (MEFs) and MCPIP1-/- fibroblasts were transfected with FuGENE 6 (Roche) or 
FuGENE HD (Promega). siRNA transfections in all cell types were performed using 
Dharmacon Transfection Reagent 1, purchased from Thermo Scientific (Catalog Number: T-
2001). Luciferase assays were performed as described previously [73] with the Dual-Luciferase 
Reporter Assay System, Promega (Catalog number: E1980). Human subject research was 
performed in accordance with protocols approved by the Institutional Review Board (IRB) of 
the University of Pittsburgh. 
2.1.2 Plasmids 
Plasmids encoding murine IL-17RA, its point mutants, and truncation mutants were constructed 
as described previously [33, 90, 99]. Plasmids encoding murine A20 and its mutants were 
obtained from the plasmid repository at BCCM/LMBP (Belgian Coordinated Collections of 
Micro-organisms/ Laboratory of Molecular Biology–Plasmid collection) (Belgium) [100]. 
 24 
Plasmids encoding human MCPIP1 as well as MCPIP1 mutants were obtained from Dr. 
Pappachan Kolattukudy at University of Central Florida and have been previously described 
[101]. Other plasmids mentioned in this study were cloned using primers listed in Table 2.2. 
2.1.3 Cytokines 
Murine IL-17 used to stimulate cells in vitro was obtained from PeproTech (Catalog number: 
210-17). Murine TNF-α (315-01A) and Human IL-17 (300-01A) were also purchased from 
PeproTech. All the above-mentioned cytokines were reconstituted to appropriate concentrations 
using PBS containing carrier protein (final concentration: 0.1% BSA). 
Murine IL-17 used for intranasal challenge in mice was purchased from R&D Systems 
(421-ML-025/CF) and was reconstituted in PBS without the carrier protein (BSA). 
2.1.4 Inhibitors 
IKK inhibitor VII was purchased from Calbiochem, EMD Millipore (Catalog number: 401486) 
and used at a final concentration of 0.1uM. 
2.1.5 Mice 
MCPIP1-/- mice were acquired from Dr. Pappachan Kolattukudy, University of Central Florida 
under an approved materials transfer agreement (MTA). These mice were crossed to IL-17RA-/- 
mice (MTA with Amgen) to generate MCPIP1-/-IL-17RA-/-. WT mice were ordered from The 
Jackson Laboratories (Bar Harbor, ME) in the C57BL/6 background. In all experiments, mice 
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were matched according to gender and age (ranging from 7 to 11 weeks). Animal protocols 
were approved by the University of Pittsburgh IACUC, and adhered to guidelines in the Guide 
for the Care and Use of Laboratory Animals of the NIH. 
2.1.6 Antibodies 
The primary antibodies used for western blot analysis have been listed in Table 2.1 along with 
the dilutions used for the detecting protein of interest. 
Table 2.1: List of Antibodies 
Antibody Company Catalog # Dilution 
A20 Cell Signaling 5630 1:1000 
Act1 (H-300) Santa Cruz sc-11444 1:1000 
β-TUBULIN Invitrogen 32-2500 1:1000 
ERK- Total Cell Signaling 9102 1:1000 
ERK-Phospho Cell Signaling 9106 1:1000 
FLAG-tag Sigma F 3165 1:1000 
HA-tag Sigma H 3663 1:1000 
IkBα (C-21) Santa Cruz sc-371 1:1000 
IkBα (Phospho) Cell Signaling 9246 1:1000 
IL-17RA R&D AF448 1:200 
JNK- Total Cell Signaling 9252 1:1000 
JNK- Phospho Cell Signaling 9251 1:1000 
MCPIP1 (P-12) Santa Cruz sc-136750 1:400 
Myc-tag (9B11) Cell Signaling 2276 1:1000 
MyD88 Santa Cruz sc-11356 1:1000 
p38- Total Cell Signaling 9211 1:1000 
p38- Phospho Cell Signaling 9212 1:1000 
TRAF3 (C-20) Santa Cruz sc-949 1:1000 
TRAF6 Santa Cruz sc-7221 1:1000 
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2.1.7 Cloning Primers 
Table 2.2: Cloning Primers 
Gene Description Primer Sequence (5’ to 3’) 
Anapc7 Fwd GAC AAG CTT CG GTT CCC GGG AGT TCT GTC C 
CGT 
Anapc7 Rev w/d stop codon GC TCT AGA TCA CTG CAT GCC GAA CCA CTG CT 
Anapc7 Rev w/o Stop codon GC TCT AGA CTG CTG CAT GCC GAA CCA CTG CT 
Act1 ΔSEFIR Fwd TG GGA TCC ATC AAC CGA AGC ATT CCC GTG 
Act1 ΔSEFIR Rev CT GAA TTC TCA TTC TGG CAA ATT GCT GGT 
Act1 ΔUbox-set1 Fwd TG GGA TCC ATC AAC CGA AGC ATT CCC GT 
Act1 ΔUbox-set1 Rev GTA GAG CTG GTC TTC AAA CTG AGG TGG CAA 
TTC 
Act1 ΔUbox-set2 Fwd CCT CAG TTT GAA GAC CAG CTC TAC CGC CCA 
Act1 ΔUbox-set2 Rev CT GAA TTC TCA CAA GGG TAC CAC CTG AAG 
MCPIP1 Fwd with Flag tag GC AAG CTT ATG GCC GAC TAC AAA GAC GAT GAC 
GAC AAG GCC AGT GAC CCT TGT GGA 
MCPIP1 Rev AGCA GC GGC CGC TTA CTC ACT GAG GTG C 
Anapc5 Fwd GA ATG ATG ACC AAC GGG GTA GTG 
Anapc5 Rev w/o stop GT TCT AGA TGC GAG GTG GTT AAT CAA GGG 
Anapc5 Rev w/d stop GT TCT AGA CTA GAG GTG GTT AAT CAA GGG 
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2.1.8 Quantitative Reverse Transcriptase PCR Primers 
Primers used in qPCR assays were either designed in-house (Table 2.3) or purchased from 
Qiagen (Table 2.4).  
 
Table 2.3: Self-designed qPCR Primers 
Gene Symbol  Primer Sequence (5’ to 3’) 
Anapc7 
Fwd 
Rev 
GCG TCC AGG CTC TGT TAC TC 
CGT AAC AGT CCA AGC GAC AA 
Anapc5 
Fwd 
Rev 
GTC CTT TGC CGT CGC TCT CT 
TCG GTC CTT CAA GTG CTT TA 
Zc3h12a (MCPIP1) 
Fwd 
Rev 
GTG TCC CTA GAG GCT GAA CC 
GCA CAG GTC TGC GGT GAG CC 
Tnfaip3 (A20) 
Fwd 
Rev 
ACC CCA GCT ATC ACT CAT GG 
TTT GGG AGC TTG CTC TGA TT 
Traf3 
Fwd 
Rev 
CCC TGG AGA AGA AGG TTT CC 
CCT TCT GCC TCT CAA TCT CG 
Cyld 
Fwd 
Rev 
CGC ATG CAG TTC TGT TTG TT 
ACG TCT ACC TGG AGG CCT TT 
Traf3ip2 (Act1) 
Fwd 
Rev 
CTT CCA AAC TGC GAT TGA CA 
GGG GCT GAT TGC TAC GAT TA 
Traf6 
Fwd 
Rev 
AAA CCA CGA AGA GGT CAT GG 
TCC CTG TCT TAA GGC TTC CA 
Il17rc 
Fwd 
Rev 
GGT ACT GTC CCC AGG GGT AT 
TTC ACA GTG GCG TTC TTC TG 
Il17ra (C-terminal) 
Fwd 
Rev 
TGC TTA GGT TCC AGG AGT GG 
CAG CAG TGG GTC TTC AAA CA 
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Table 2.4: Commercial qPCR Primers 
 
Gene Symbol 
 
Catalog Number 
Anapc7 (m) PPM28440A 
Anapc5 (m) PPM41082B 
Ccl20 (m) PPM03142B 
Cd4 (m) PPM04028F 
Cd8 (m) PPM04031A 
Csf2 (m) PPM02990F 
Csf3 (m) PPM02989B 
Cxcl1 (m) PPM03058C 
Cxcl2 (m) PPM02969E 
Cxcl5 (m) PPM02966F 
Gapdh (m) PPM02946E, QT01658692 
Gapdh (h) PPH00150F 
Ifng (m) PPM03121A 
Nfkbz (m) PPM34845A 
Il17a (m) PPM03023A 
Il17ra (m) QT00112063 
Il17ra (h) QT02451078 
Il6 (m) PPM03015A 
Il6 (h) PPH00560C 
Itch (m) QT01048684 
Lcn2 (m) PPM03770A 
Tax1bp1 (m) PPM60164A 
Tnf (m) PPM03113G 
Tnfaip3 (m)  PPM03207A 
Traf3 (m) PPM03088E 
Zc3h12a (m) PPM24532A, QT01166480 
Zc3h12a (h) QT00229838 
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2.1.9 Small Interfering RNA (siRNA) 
SMARTpool ON-TARGETplus siRNA targeting the gene of interest as well as Non-targeting 
scrambled siRNA (control) were acquired from Dharmacon, Thermo Scientific. The siRNA 
pool were reconstituted in 1X siRNA buffer (Catalog number: B-002000) at a concentration of 
50uM and used at a final concentration of 50nM. 
 
Table 2.5: On Target plus siRNA Sequences 
Gene Symbol Organism siRNA Sequence (5’ to 3’) 
Anapc7 Mouse 
GGA UGG AUG UUU ACG GCU A 
CGU GUG GAU UAA AGC GUA U 
CGA UAA GGA GUA CCG CAA U 
GCA AAC GCU CAG ACG CUU A 
Traf3ip2 (Act1) Mouse 
GCU CAG AUA UAG UAG UAG A 
CCG UGG AGG UUG AUG AAU C 
CAG AUG UGC CCA CGA UAG A 
UGC CAG AAG AAU UAC GGA A 
Anapc5 Mouse 
UCA CAA AAC GAG UGU AGU A 
CCG CUU UGU UGA AGA AUG A 
AUG CUG AUA UGG ACC GAG A 
AGG AAG AGC UCG ACG UGU C 
Zc3h12a (Mcpip1) Mouse 
GGA AAC GCU UCA UCG AGG A 
UGG ACA ACU UCC UUC GUA A 
CGA GAA GGC UCA CCG CAG A 
AGU ACU GGU CUG AGC CGU A 
Tnfaip3 (A20) Mouse 
AGA GAC AUG CCU CGA ACU A 
GCU GUG AAG AUA CGA GAG A 
UGU UAC UGC CUC UGC GAA A 
GCA CCU AAG CCA ACG AGU A 
Traf3 Mouse 
GAC AAG UAC AAG UGC GAG A 
GAA AUG UAA CCC UUC GAU A 
CCU CAC AAG UGC AGC GUU C 
CUA GAG AAC GGG ACG UAU A 
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Tnfaip3 (A20) Human 
CUG CAG UAC UUG CUU CAA A 
CAA CUC AUC UCA UCA AUG C 
UCU GGU AGA UGA UUA CUU U 
CAA CGA AUG CUU UCA GUU C 
Itch Mouse 
CAU CUC AGC CAA ACU UAA A 
CAG CUU GAU UCC AUG GGU A 
GAA ACG UCA UGC UCC GAG A 
AUU GGG AAC UGC UGG AUU A 
Tax1bp1 Mouse 
UGA AAU UCG UGG AGC AAG U 
GAA CGA UGC UUC AAU AAA U 
CUA ACU ACG AUC AGA CCA A 
GAU GAA GGC AAU UCC GAU A 
Usp25 Mouse 
GCA CGA ACU CUG UGA GCG A 
UAA UGU ACA UAG ACG ACA A 
AAA CAA UAA ACC CGA GAA U 
GAG AAA UGU CCU CUA CUA A 
Cdc27 Mouse 
CUA UAU GGC AAG CGC UAA A 
AGG CAA UUG ACA AGC GCU A 
CGG CGG AAA GUG ACG AAU U 
CAA AUU ACG CUU ACG CCU A 
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2.2 METHODS 
2.2.1 Mouse Tail Tip Fibroblast generation 
Mice were euthanized and about one inch of the distal tail was harvested. The tails were cut into 
smaller pieces using a sterile razor blade in a 10 cm tissue culture plate containing 
approximately 500 ul of 2% PenStrep in 1X PBS. The tail pieces were transferred to 15 ml 
conical tubes and additional PBS with PenStrep added to make the volume 1 ml. Next, an equal 
amount of collagenase (final concentration= 1000U/ml) was added and the tubes incubated at 
37°C for 20-30 minutes. The tubes were mixed every few minutes to ensure effective 
collagenase treatment. After the incubation, the tubes were spun at 1200 RPM for 5 minutes and 
washed once with Hank’s Balanced Salt Solution (HBSS). Then, 2-3 ml of trypsin was added 
and tubes were incubated at 37°C for 20 minutes. After this incubation, equal amount of media 
with FBS was added to the tubes and the tubes were spun at 1200 RPM for 5 minutes. The 
pellet of tissue and cells was re-suspended in 3-4 ml of complete media (with 20% FBS) and 
transferred to T25 tissue culture flasks. The tissue pieces were kept in the flask until there was a 
layer of fibroblasts covering the whole flasks after which the cells were split into two flasks and 
cultured. To immortalize the cells, the fibroblasts were transfected with 1 ug SV40 T antigen (6-
well plate) and cultured for a few passages until the growth advantage was clearly visible. Both 
primary as well as immortal cells were frozen and stored in liquid nitrogen for later use. 
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2.2.2 ELISA, Immunoprecipitation and Immunoblotting 
Murine and human IL-6 enzyme linked immunosorbent assay (ELISA) kits were from 
eBioscience, and the CCL20 ELISA kit was from R&D Systems. For each experiment, each 
sample was analyzed in duplicate or triplicate, and minimum of three replicate samples were 
included per experiment. Manufacturer’s protocols were followed to run these assays. 
Cells were lysed using 1% NP-40 lysis buffer containing protease inhibitors, sodium 
orthovandate and PMSF, unless otherwise stated. Total protein in the lysis buffer was quantified 
using a BCA assay kit (Thermo Scientific, Catalog number: 23227). In most cases, 
approximately 30-35 ug of total protein was loaded for analysis. Antibodies used have been 
listed in Table 2.1. The blots were developed using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Catalog number: 34080). For detecting endogenous protein, the 
substrate was spiked with 20-40 ul of SuperSignal West Femto Reagent (Thermo Scientific, 
Catalog number: 34094). 
Immuno blotting analysis and immunoprecipitations were performed as described 
previously [57, 99], and bands on blots corresponding to proteins of interest were analyzed by 
ImageJ software or on a ProteinSimple FluorChem E instrument/software. 
2.2.3 In vitro Cytokine Stimulation 
IL-17 (murine and human) was used at a final concentration of 200 ng/ml, unless otherwise 
stated. Final concentration for TNF-α was 2ng/ml when used by itself or in synergy with IL-17. 
Stimulation times varied between experiements and are mentioned along with individual 
experiments. 
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2.2.4 siRNA Transfection 
ON-TARGETplus SMARTpool siRNA targeting the gene of interest as well as scrambled 
controls were obtained from Dharmacon/Thermo Scientific. Lyophilized siRNA were 
reconstituted in 1X siRNA buffer at a stock concentration of 50 uM. The siRNA stocks were 
frozen at -20°C in 10 ul aliquots. The stocks were diluted to 5 uM at the time of transfection and 
used to make the final transfection mixture. 
For transfecting siRNA, ST2 cells (approximately 10-15 thousand cells per well) were 
seeded overnight in antibiotic-free medium (0.5ml per well) in 24-well tissue culture plates. The 
next day, these cells were transfected with 50 nM siRNA with DharmaFECT Reagent 1 
(Dharmacon/Thermo Scientific) according to the manufacturer’s protocol. DharmaFECT 
Reagent 1 is a liposomal transfection reagent and works well with a majority of murine and 
human cell lines. Twenty-four hours after transfection, the culture medium was changed. The 
cells were incubated in medium alone for additional 24 hours after which these cells were 
stimulated with IL-17 for the times indicated with each individual experiment. For each 
experiment, three replicate samples were analyzed separately.  Cells were visually checked 
periodically to make sure that the transfection of siRNA was not toxic to these cells. To assess 
the efficiency of knockdown by immunoblotting, the siRNA knockdown protocol was scaled up 
to a 6 cm or 10 cm (diameter) dish. The cells were lysed in minimal volume of lysis buffer (50 
ul) and quantified for total protein. Approximately 30 ug of total protein was loaded for western 
blot analysis. 
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2.2.5 mRNA Extraction and qPCR 
Total RNA from cells and tissues was isolated with an RNeasy Mini Kit (Qiagen). Cells in the 
lysis buffer were homogenized by passing them 10 times through a 20-gauge needle, whereas 
tissues (Kidneys, lungs, spinal cords, intestines) were homogenized by using M tubes and 
gentleMACS Dissociator (Miltenyi Biotech). The amount of lysis buffer used for tissue lysis 
was dependent on the amount of tissue, and approximately 25-30 ul of lysis buffer was used per 
mg of tissue. The homogenates were spun down 3 times to get rid of all the tissue debris before 
proceeding with addition of 70% ethanol and proceeding with the steps suggested in the 
supplier protocol. RNA concentration was measured using a nanodrop. 
Complementary DNA synthesis was performed with SuperScript III First-Strand 
(Invitrogen). The extent of expression of genes was determined by quantitative PCR (qPCR) 
analysis with PerfeCTa SYBR Green FastMix ROX (Quanta BioSciences). The PCRs were 
performed on a 7300 Real-Time PCR System (Applied Biosystems). The abundances of the 
mRNAs of interest were normalized to that of Gapdh. Primers for this assay were either self 
designed or purchased from Qiagen and have been listed in Table 2.3. 
2.2.6 Candida albicans Culture and Disseminated Candidiasis mouse model 
For infection, C. albicans (strain CAF2-1) was grown overnight (approximately 16 hours) in 
YPD broth at 30°C with continuous agitation. 
For the disseminated candidiasis infection model, the number of C. albicans cells per ml 
of YPD broth were counted using haemocytometer. On average, overnight growth resulted in 3-
4 x 108 C. albicans cells per ml. C. albicans was serially diluted in sterile PBS to obtain a final 
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concentration of 2x106 C. albicans cells per ml. Mice were injected with 100ul of this dilution 
in their tail veins using a 27 gauge needle. 
Assessment of fungal burden in the kidney was done two days post infection. Mice were 
euthanized and both the kidneys were harvested and sliced longitudinally. One half of a kidney 
was snap frozen in micro-centrifuge tubes using liquid nitrogen whereas another half from the 
other kidney was fixed using 10% NBF for histological analysis. The two remaining halves 
were weighed and added to 1 ml of PBS. Homogenization of these tissues was carried out in C-
tubes (Millipore). Several dilutions of these tissue homogenates were plated on plates with YPD 
agar containing ampicillin. The plating was either carried out by spreading the homogenates on 
the plates or by spotting 25 ul aliquots of these dilutions. All the samples were plated in 
triplicates and the calculations were modified based on the amount of homogenate plated. These 
plates were incubated at 30°C for 48 hours and the C. albicans colony forming units (cfu) were 
counted. The fungal load was reported as total cfu per gram of tissue. 
2.2.7 Intranasal IL-17 challenge and Pulmonary Inflammation model 
For IL-17-induced pulmonary inflammation, age- and sex-matched mice were treated with IL-
17 (300ng per mouse) by intranasal injection or left unchallenged. 24 hours later, 0.5 ml PBS 
(containing 0.5 mM EDTA) was used to obtain bronchoalveolar lavage fluid (BALF) though the 
trachea. Furthermore, 4ml PBS was used to acquire BALF from the lungs. Supernatants from 
the first lavage were used for ELISA and precipitates from all 5ml of BALF were combined and 
analyzed for lung-infiltrating cells. Cells were counted using haemocytometer and then were 
stained with anti-CD11b, anti-Gr-1 and anti-F4/80 antibodies, followed by flow cytometry. Left 
lobe of lung was snap frozen in eppendorfs for qPCR analysis, whereas the rest of the lungs 
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were homogenized in 1 ml of ice cold PBS containing protease inhibitors (Roche). These 
homogenates were also analyzed for inflammatory cytokine and chemokine protein levels. 
2.2.8 Experimental Autoimmune Encephalomyelitis (EAE) - Mouse Model of Multiple 
Sclerosis 
C57BL/6 mice (both WT and MCPIP1+/-) were immunized subcutaneously in four sites on the 
back with a total of 100 mg myelin oligodendrocyte glycoprotein (MOG) peptide (35–55) in 
200 ul incomplete CFA mixed with 100 mg M. tuberculosis strain H37Ra (DIFCO, Michigan, 
USA). All mice also received 100 ng pertussis toxin (List Biological Laboratories) 
intraperitoneally on days 0 and 2. Mice were assessed daily for symptoms of paralysis and 
assigned clinical scores for EAE according to the following scale: 1, flaccid tail; 2, impaired 
righting reflex and hindlimb weakness; 3, partial hindlimb paralysis; 4, complete hindlimb 
paralysis; 5, hindlimb paralysis with partial forelimb paralysis; 6, moribund. If an animal had a 
clinical score or 5 or more for two consecutive days, it was euthanized for humane reasons. At 
the end of the experiment, mice were euthanized and their spinal cords were harvested and snap 
frozen using liquid nitrogen for RNA analysis. 
2.2.9 Flow Cytometry 
For staining surface IL-17RA, one million HEK293T cells were washed and treated with 100 ul 
Fc block antibodies (1:100). These cells were then washed and stained with a non-commercial 
primary antibody (1:1800) from Amgen (Clone: m751: 78997-88, Concentration: 4.62 mg/ml) 
 37 
for approximately 45 minutes on ice. Finally, the cells were counterstained with a secondary 
antibody (1:100) (anti-Mouse PE or anti-Mouse APC) from Becton Dickinson (BD).  
To assess the neutrophil infiltrate in the BALF, the cells were first treated with Fc block. 
For staining neutrophils and macrophages, the cells were stained with anti-Gr1 (Alexa Fluor 
700) and anti-F4/80 (PE) respectively at a dilution of 1:100. The samples were analyzed using 
LSRII in the Department of Immunology, University of Pittsburgh. 
2.2.10 Statistics 
To assess statistical significance, we used Student’s t test (for pairwise comparisons) or 
ANOVA with post Tukey’s analysis (for more than two comparisons in an experiment). In 
some cases, Chi Square test was used to compare experimental replicates. P < 0.05 was 
considered statistically significant. Error bars reflect the means ± SEM of biological replicates 
within individual experiments. All experiments were repeated a minimum of two times to 
ensure reproducibility.  
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3.1 BACKGROUND 
Inflammatory cytokines, such as TNF-α, have long been recognized to promote the 
pathogenesis of devastating autoimmune diseases such as RA, among many others [102]. It is 
not an exaggeration to say that biologic therapies targeting TNF-α and other inflammatory 
cytokines revolutionized the clinical management of many of these diseases. Despite these 
advances, many patients fail to respond to available anti-cytokine therapies, and some diseases 
do not respond to anti-TNF drugs. In the last several years, IL-17 emerged as a key player in 
autoimmune inflammation, and new clinical trial data indicate exciting promise for anti-IL-17 
drugs in treating psoriasis and other autoimmune conditions [54, 103-105]. IL-17 is produced 
by a recently defined subset of CD4+ T cells termed TH17 cells, and a fast-moving body of 
literature has described many mechanisms by which TH17 cells are generated and regulated [23, 
106]. In addition, it is increasingly apparent that IL-17 is produced by many innate cell types, 
which bear marked similarities to classic TH17 cells and participate in mediating autoimmune 
inflammation [30]. 
In contrast to the efforts focused on investigating the immunology of TH17 cells, there 
has been far less emphasis on understanding how IL-17 activates downstream signaling 
pathways. IL-17 is the founding member of a distinct subclass of cytokines and receptors that 
exhibit unique signaling properties compared to those of the better-defined cytokine receptors, 
such as the TNFR superfamily or the IL-1 receptor and TLR families [107]. However, IL-17 
shares similar signaling endpoints to those of other inflammatory cytokines, particularly in 
terms of activation of NF-κB and MAPK signaling, as well as induced expression of genes 
encoding pro-inflammatory cytokines [such as IL-6 and G-CSF], antimicrobial peptides 
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[including lipocalin 2 (also known as 24p3)], S100A proteins, and β-defensins, and chemokines 
(including CXCL1, CXCL5, and CCL20) [31]. The net effect of IL-17 signaling is effective 
host defense against bacterial and especially fungal infections. Indeed, in humans, mutations in 
the gene encoding IL-17R or in genes whose products control TH17 development, such as 
STAT3 or STAT1, cause increased susceptibility to infections by the commensal fungus Candida 
albicans [108, 109]. Conversely, excess IL-17 is associated with numerous autoimmune 
diseases, and many genes identified as risk loci for autoimmunity in genome-wide association 
studies (GWAS) (for example, IL23R and STAT3) are associated with regulation of IL-17 or the 
TH17 differentiation pathway [47, 110]. 
IL-17 mediates signaling through a heterodimeric receptor composed of IL-17RA and 
IL-17RC [18]. Both subunits contain a signaling motif unique to the IL-17R family known as a 
SEFIR domain [61]. The SEFIR provides a platform for binding of Act1 (also known as CIKS), 
a SEFIR-containing adaptor protein and E3 ubiquitin ligase [61, 66, 67, 70, 111]. IL-17 
engagement recruits Act1 to the receptor complex. In turn, Act1 recruits and activates TRAF6, 
ultimately leading to activation of transcription factors, such as NF-κB and C/EBPβ and 
C/EBPδ, as well as MAPKs [65, 112]. The C-terminal domain of IL-17RA, in contrast, is 
required for activation of C/EBPβ and is linked to inhibitory signaling through GSK-3β and 
TRAF3 [33, 89, 90, 99]. 
Ubiquitination is a posttranslational modification that is essential for modulating pro-
inflammatory pathways [113]. Ubiquitination involves covalent linking of ubiquitin (Ub) 
moieties to target proteins through specific lysine residues, and is regulated by a cascade of E1 
(Ub-activating), E2 (Ub-conjugating), and E3 (Ub-ligase) enzymes. Of the seven lysines in 
ubiquitin, K48 and K63 are most commonly used to form polyubiquitin chains. K48-linked Ub 
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generally targets proteins for proteasomal degradation, whereas K63-linked Ub triggers non-
degradative functions, such as protein-protein interactions and cell signaling events [114]. 
Notably, many of the currently identified IL-17R–proximal proteins are E3 ubiquitin ligases. 
For example, the E3 ligase activity of Act1 is required for the K63 ubiquitination of TRAF6, 
which is also an E3 Ub ligase [70, 115, 116]. Ubiquitination of TRAF6 is a key event in the 
downstream activation of both NF-κB as well as MAPK pathways [18, 68, 70]. 
Reversal of ubiquitination is equally important in regulating inflammation, particularly 
to keep potentially damaging signals in check [117-119]. A20 is a DUB and tumor suppressor 
encoded by TNFAIP3 (TNF-α–induced protein 3), and was first identified as an inhibitor of the 
TNFR signaling pathway [120, 121]. Subsequent studies identified roles for A20 in inhibiting 
the TLR, IL-1R, and Nod-like receptor (NLR) pathways [117, 122, 123]. In the TNFR pathway, 
the E3 ubiquitin ligase and adaptor protein TRAF2 and the kinase ribosome inactivating protein 
(RIP) 1 are targets of A20, whereas in IL-1R and TLR signaling, TRAF6 is a key A20 target 
(Figure 3.1). Deubiquitination of these adaptors restricts activation of the NF-κB and MAPK 
pathways [114, 117, 124]. Confirming its essential role in restraining inflammation, A20-
deficient (A20-/-) mice develop spontaneous multi-organ inflammation and die shortly after birth 
[124], and mice with cell-type specific knockout of A20 are prone to multiple autoimmune 
diseases [123, 125-127]. Moreover, polymorphisms in the TNFAIP3 locus are associated with 
increased susceptibility to RA, lupus, systemic sclerosis, Crohn’s disease and psoriasis [126, 
128]. Here, we show that A20 is a feedback inhibitor of the IL-17 signaling pathway. IL-17 
increased the expression of Tnfaip3 mRNA and subsequent production of A20 protein, which 
inhibited IL-17-mediated activation of TRAF6, NF-κB, and MAPK as well as downstream gene 
expression. Furthermore, A20 bound to a domain of IL-17RA that is associated with inhibiting 
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receptor signaling [99]. Thus, these findings expand the known regulatory role of A20 in 
regulating inflammatory signaling, and lend new insight into how IL-17-driven inflammation is 
controlled. 
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Figure 3.1: A20-mediated inhibition of proinflammatory signaling pathways. 
A20 is induced by multiple proinflammatory stimuli and acts as a feedback inhibitor of its 
inducing signaling pathways. 
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3.2 RESULTS 
3.2.1 IL-17 induces TNFAIP3 expression and production of A20, which is dependent on 
NF-κB. 
As its name implies, TNFAIP3 was first identified as a TNF-α–induced gene [129], and its gene 
product A20 serves as a feedback inhibitor of NF-κB [124]. Based on similarities in the 
downstream pathways regulated by IL-17 and TNFα, we hypothesized that A20 might also 
participate in inhibition of the IL-17 signaling pathway. Although produced primarily by T 
cells, IL-17 exerts its biological effects primarily in the non-hematopoietic compartment, 
particularly on mesenchymal cell types such as fibroblasts and stromal cells [130]. Accordingly, 
we stimulated ST2 cells (a murine stromal cell line) with IL-17 over a time course of 24 hours 
and assessed endogenous TNFAIP3 mRNA abundance by quantitative real-time reverse 
transcription polymerase chain reaction (qPCR). IL-17-induced expression of TNFAIP3 
occurred within 15 min of stimulation (Figure 3.2-A). Expression peaked at 30 min after 
treatment and remained increased at 4- to 5-fold above baseline for at least 24 hours. These 
kinetics are similar to those reported for TNF-α–induced expression of TNFAIP3 [124]. We 
verified that endogenous A20 protein was also induced by IL-17, at slightly delayed kinetics 
compared to mRNA expression (Figure 3.2-A). A20 transcription was previously reported to be 
regulated at the promoter level by various transcription factors, including NF-κB [129]. 
Consistently, an IKK inhibitor blocked IL-17-mediated induction of A20 mRNA in ST2 cell, 
implicating NF-κB in this pathway (Figure 3.2-B).  
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Figure 3.2: IL-17 induces TNFAIP3 expression and production of A20, which is dependent 
on NF-κB.  
(A) Left: Rapid induction of endogenous TNFAIP3 mRNA expression by IL-17. ST2 cells were 
treated with IL-17 (200 ng/ml) for the indicated times and A20 mRNA abundance was assessed 
by qPCR in triplicate assays. Data are presented as the fold-induction in TNFAIP3 (A20) 
mRNA abundance compared to untreated cells. Right: Endogenous A20 or β-Tubulin assessed 
by immunoblotting of ST2 cell whole cell lysates treated with IL-17 for the indicated times. (B) 
IL-17 induction of endogenous A20 is mediated by the NF-κB pathway. ST2 cells were treated 
with IL-17 for 30 min in the presence of DMSO or an IKK inhibitor (0.1 µM), and TNFAIP3 
was assessed by qPCR in triplicate assays. *P < 0.05 by ANOVA with post-hoc Tukey’s test, 
compared to untreated (at 0 min). 
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3.2.2 A20 inhibits IL-17 signaling. 
Because inhibitory molecules are often induced by the cytokines that they suppress, we 
hypothesized that A20 would inhibit IL-17–mediated signaling. We transfected ST2 cells with 
siRNA specific for A20, using a non-targeting scrambled siRNA as a negative control. As a 
positive control, we evaluated siRNA specific for Act1, which positively activates IL-17R 
signaling [66, 67]. Forty-eight hours after transfection, cells were stimulated with IL-17 for 1.5 
or 3 hours, and IL-6 in culture supernatants was measured by ELISA (Figure 3.3-A). As 
expected, IL-6 production increased even in untreated cells after transfection with A20-specific 
siRNA, indicating that A20 controls the tonic expression of pro-inflammatory genes [121]. 
Stimulation with IL-17 in combination with A20 knockdown led to a significant (P <0.001) 
increase in IL-6 production compared to that by stimulation with IL-17 alone, revealing an 
inhibitory role for A20 in the IL-17 pathway (Figure 3.3-A). We verified that A20 was 
efficiently knocked down in these experiments (Figure 3.3-B,C). To determine whether 
induction of A20 by IL-17 leads to termination of IL-6 expression, we evaluated the kinetics of 
Il6 mRNA induction following IL-17 treatment. There was a slight drop at the 1- and 1.5-hour 
time points coinciding with the time when A20 protein was increased, but generally Il6 mRNA 
was maintained at steady state for at least 4 hours (Figure 3.3-D). This finding supports a model 
in which A20 serves to keep IL-17 signaling in check, but does not cause complete signal 
termination. 
To further evaluate the role of A20 in IL-17 signal transduction, we analyzed expression 
of a panel of well-defined IL-17 target genes in the context of A20 silencing [69, 72, 131]. 
Consistent with an increase in IL-6 protein abundance, transfection with A20-specific siRNA 
enhanced IL-17–dependent induction of Il6 expression. Similarly, knockdown of A20 enhanced 
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IL-17–induced expression of Ccl20, Lcn2 (which encodes lipocalin 2), Csf3 (which encodes G-
CSF), and Cxcl1, and Cxcl5 (Figure 3.4-A). Although the magnitude by which A20-specific 
siRNA enhanced the expression of IL-17 target genes was variable, the extent of expression of 
all of these genes was significantly and reproducibly increased. However, there was no change 
in the expression of Ikbz in response to A20 knockdown (Figure 3.4-A), suggesting that there 
may be distinct modes of regulation for some IL-17-induced genes. 
Increased amounts of IL-17 as well as an increase in the extent of expression of IL-17–
induced genes are associated with pathology in RA [132]. Accordingly, we tested the effect of 
A20 knockdown in human primary fibroblast-like synoviocytes (FLSs), a cell type that 
mediates pathogenesis in the inflamed joint. Transfection of FLS cells with A20 siRNA led to 
enhanced IL-17–dependent IL-6 production compared to control transfected cells (Figure 3.4-
B). Therefore, we conclude that A20 mediates feedback inhibition of IL-17 signaling, and that 
this regulation has the potential to be relevant in a disease where IL-17 plays a well-documented 
role. 
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Figure 3.3: A20 inhibits IL-17 signaling.  
(A) Knockdown enhances the production of IL-6 protein. ST2 cells were transfected with 
siRNA specific for Act1 or A20 or with a scrambled siRNA control, and the amount of IL-6 in 
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culture media was assessed in triplicate at 1.5 and 3 hours after treatment with IL-17 (200 
ng/ml). Black bars indicate IL-17-treated samples, and white bars indicate untreated samples. 
*P <0.05 by ANOVA with post-hoc Tukey’s test compared to cells transfected with control 
siRNA and treated with IL-17. (B, C) Successful knockdown of TNFAIP3 mRNA and protein. 
TNFAIP3 mRNA in cells treated with siRNA was assessed by qPCR. After siRNA-mediated 
knockdown of TNFAIP3 expression, the indicated cell lysates were analysed by western 
blotting for A20 protein (top) or β-tubulin (bottom) as a loading control. (D) Kinetics of IL-17-
induced IL-6 production. ST2 cells were treated with IL-17 for the indicated times and IL-6 
mRNA assessed by qPCR, normalized to the zero time point.  
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Figure 3.4: A20 knockdown suppresses IL-17-mediated gene expression. 
(A) A20 knockdown enhances expression of most but not all IL-17 target genes. ST2 cells 
transfected with the indicated siRNAs and left untreated or treated with IL-17 for 3 hours were 
analyzed for the expression of the indicated genes by qPCR. (B) A20 knockdown enhances IL-
17R signaling in human FLS cells. FLS cells were transfected in triplicate with the indicated 
siRNAs and IL-6 secretion after 4 or 24 hours of IL-17 stimulation was assessed by ELISA in 
triplicate. *P <0.05 by ANOVA and post-hoc Tukey’s test compared to cells transfected with 
control siRNA and treated with IL-17. 
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3.2.3 Overexpression of A20 inhibits IL-17 target promoter activation. 
NF-κB is required for activation of many IL-17 target genes, including 24p3/lipocalin 2 and IL-
6 [72, 73]. To determine whether A20 impacts NF-κB-dependent promoters regulated by IL-17, 
ST2 cells were transfected with luciferase (Luc) constructs driven by the 24p3/lipocalin 2 or IL-
6 promoters in combination with increasing concentrations of A20 [72, 73]. IL-17 stimulation 
triggered a ~2.5-fold increase in 24p3-Luc activity over baseline (Figure 3.5-A). Co-
transfection with A20 resulted in a dose-dependent reduction in 243p-Luc, supporting a model 
in which A20 inhibits IL-17 activation of this gene at the level of the promoter. A mild 
suppression in luciferase activity was also seen in cells treated without cytokines, consistent 
with the effect of A20 on tonic signaling noted in Figure 3.3. Parallel results were obtained with 
the IL-6 promoter (Figure 3.5-B). Further evidence for a role for A20 in suppressing target 
promoter activation came from the observation that IL-17-mediated induction of the 24p3 
promoter was more strongly enhanced in A20-deficient cells compared to cells reconstituted 
with A20 (Figure 3.5-C).  Together, these data support the concept that A20 inhibits IL-17 by 
modulating NF-κB-regulated gene expression. 
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Figure 3.5: A20 suppresses IL-17-mediated activation of NF-κB-dependent gene 
promoters. 
(A, B) Ectopic expression of A20 suppresses IL-17 activation of the 24p3 and IL-6 promoters. 
ST2 cells were transfected with luciferase constructs encoding the 24p3/lipocalin 2 promoter or 
the IL-6 promoter together with increasing concentrations of A20 plasmid DNA. After 8 h of 
IL-17 treatment, luciferase activity was assessed, normalized to samples transfected with 
control DNA and treated with no cytokines. (C) A20-deficency leads to enhanced IL-17 
activation of the 24p3 promoter. A20-/- MEFs were transfected with the 24p3-Luc construct and 
either an empty vector (EV) or a plasmid encoding A20. After 8 hours of IL-17 treatment, 
luciferase activity was assessed, normalized to samples transfected with control DNA and 
treated with no cytokines. *P <0.05 by ANOVA and post-hoc Tukey’s test, compared to 
unstimulated EV sample. 
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3.2.4 Reconstitution of A20-/- MEFs reverses IL-17 induced target gene expression. 
To verify independently that A20 inhibits the IL-17 pathway and rule out possible nonspecific 
or off-target effects of siRNA, A20-/- murine embryonic fibroblasts (MEFs) were transfected 
with either an empty vector (EV) or a plasmid encoding murine A20. Cells were stimulated with 
IL-17 for 4 hours, and IL-6 in culture supernatants was assessed. A20-/- MEFs reconstituted with 
EV showed an IL-17-dependent increase in IL-6 production, which was reduced upon 
reconstitution with A20 (Figure 3.6-A). Production of CCL20 was similarly impacted by 
reconstitution with A20 (Figure 3.6-A). We next determined the impact of reconstituting A20-/- 
MEFs on expression of a panel IL-17 target genes. IL-17-induced expression of Il6, Ccl20, 
Cxcl1, Cxcl5, Csf3 and lcn2 mRNA in A20-/- cells was repressed upon reconstitution with A20 
(Figure 3.6-B). Similar to the findings with siRNA (Figure 3.4-A), there was only a mild effect 
of A20 reconstitution on Ikbz expression (Figure 3.6-B), indicating that A20 regulates most but 
not all IL-17 target genes. 
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Figure 3.6: Reconstitution of A20-/- cells with A20 suppresses IL-17-dependent signaling.  
(A-B) A20-/- MEFs were transfected in triplicate with EV or murine A20 and treated with IL-17 
for 4 hours. Culture supernatants were evaluated in triplicate for IL-6 or CCL20 by ELISA (A), 
and cell lysates were evaluated for the indicated mRNA transcripts by qPCR (B). *P < 0.05 by 
ANOVA and post-hoc Tukey’s test compared to IL-17-treated samples transfected with EV. 
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3.2.5 A20 reverses IL-17-mediated TRAF6 activation. 
Since TRAF6 is essential for IL-17-induced NF-κB activation [68], we asked whether IL-17 
induces association between A20 and TRAF6. A20-/- MEFs were reconstituted with or without 
A20 and stimulated over a time course of 0 to 120 min. Cell lysates were immunoprecipitated 
for TRAF6 and immunoblotted for A20. There was no detectable baseline association between 
A20 and TRAF6 ((Figure 3.7-A), lane 5). However, A20 associated with TRAF6 by 60 min. 
These kinetics are very similar to the association of A20 with TRAF6 and TRAF2, induced by 
IL-1β and TNFα, respectively [117, 133, 134] (Figure 3.7-A).  
A20 inhibits IL-1β and TNFα signaling by deubiquitinating K63-linked ubiquitin chains 
from TRAF6 and RIP1 [114, 117, 124]. To determine whether activation of A20 was associated 
with deubiquitination of TRAF6, reconstituted A20-/- cells were treated with IL-17, Act1 was 
immunoprecipitated from cell lysates, and the TRAF6 ubiquitination status was assessed by 
immunoblotting for TRAF6. Consistent with an association between A20 and TRAF6, TRAF6 
exhibited sustained ubiquitination following IL-17 stimulation for 90-120 min in A20-/- cells, as 
evidenced by increased intensity of larger migrating forms reactive to the TRAF6 antibodies 
((Figure 3.7-B), lanes 1-3). In contrast, reconstitution of A20-/- cells with A20 was associated 
with a reduced appearance of the larger migrating forms of TRAF6 ((Figure 3.7-B), lanes 4-6). 
Although the signals were weak, they were reproducible and are consistent with a recent 
published report [92]. These data probably also reflect the fact that IL-17-mediated activation of 
NF-κB is typically far more modest than classical inflammatory cytokines such as IL-1β or 
TNFα [17, 72]. 
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Figure 3.7: A20 reverses IL-17-mediated TRAF6 activation. 
(A) A20 associates with TRAF6 in an IL-17-inducible manner. A20-/- cells were transfected 
with EV (lanes 1-4) or A20 (lanes 5-8) and lysates were immunoprecipitated with antibodies 
(Abs) against TRAF6. IP samples were immunoblotted with Abs to A20 (top) and TRAF6 
(middle). Samples of whole cell lysates (WCL) were blotted for A20 (bottom) to verify 
transfection efficiency, (B) A20 mediates TRAF6 deubiquitination after IL-17 signaling. A20-/- 
cells were transfected with EV (lanes 1-3) or A20 (lanes 4-6) and lysates were 
immunoprecipitated with Abs against Act1. Lysates were blotted with α-TRAF6 Abs. Arrow 
indicates approximate migration of TRAF6 (band is obscured by IgH heavy chain). Note that 
lanes 1-3 and 4-6 are from the same gel, but the TRAF6 gel subjected to different exposure 
times to optimize visualization of larger, ubiquitinated TRAF6 bands.   
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3.2.6 A20 inhibits the IL-17-induced NF-κB/MAPK pathways. 
NF-κB is activated when IκBα is phosphorylated, ubiquitinated and degraded, resulting in 
unmasking of the NF-κB nuclear localization signal and subsequent nuclear import. IκBα 
expression is, in turn, regulated by NF-κB in a feedback loop. To determine whether A20 
inhibits IL-17-mediated induction of NF-κB, we monitored IκBα degradation in A20-/- MEFs 
reconstituted with or without A20 over 0-60 min of IL-17 treatment. Lack of A20 resulted in 
continued IL-17-induced degradation of IκΒα, suggesting prolonged NF-κB activation. 
However, in cells reconstituted with A20, this degradation was inhibited very rapidly, 
suggesting regulation of NF-κB activity (Figure 3.8-A). These data support a model in which 
A20 blocks the IL-17-induced NF-κB pathway.   
In the IL-17 pathway, TRAF6 is required for activation of MAPK [18].  Although there 
is some variation among cell types, all 3 major pathways (ERK, p38 and JNK) have been shown 
to be induced by IL-17. To determine whether A20 suppresses MAPK activation, A20-/- cells 
were transfected with EV or A20, and IL-17-induced phosphorylation of JNK, ERK and p38 
were assessed by immunoblotting. Transfection of A20 prevented prolonged phosphorylation of 
JNK, as indicated by the absence of p-JNK at the 30 and 60 min time points ((Figure 3.8-B), 
lanes 7-8).  A similar pattern was observed for p-ERK and p-p38 (Figure 3.8-B). Therefore, 
A20 suppresses MAPK activation, particularly JNK. 
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Figure 3.8: A20 inhibits the IL-17-induced NF-κB/MAPK pathway. 
(A) A20 promotes IκBα degradation. Left: A20-/- cells were transfected with EV (lanes 1-4) or 
A20 (lanes 5-8), treated with IL-17 for the indicated times, and IκBα expression (top) was 
assessed by immunoblotting. Loading of A20 (middle) and β-tubulin (bottom) is shown. Right: 
Relative band intensity from two pooled independent experiments was determined by 
densitometry + SEM, *P <0.05 by ANOVA and post-hoc Tukey’s test compared to the 
unstimulated time point for each condition. (B) A20 suppresses IL-17-inducible MAPK 
activation. A20-/- cells were transfected with EV (lanes 1-4) or A20 (lanes 5-8), stimulated with 
IL-17 for the indicated times and lysates were immunoblotted for the indicated MAPK family 
members or A20. 
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3.2.7 Inhibition of IL-17 signaling is mediated through the OTU and Zinc Finger 
Domains of A20. 
Multiple subdomains of A20 contribute to its inhibitory capacity (Figure 3.9-A) [117]. The best 
characterized is the N-terminal OTU (ovarian tumor) domain, which encodes deubiquitinase 
(DUB) activity and is proposed to be important for TRAF6 association [85, 135]. In addition, 
the seven C-terminal zinc-finger (ZnF) domains are important for A20 activity [117, 135-137]. 
In particular, ZnF4 and ZnF5 exhibit Ub-binding activity, which facilitates adaptor recruitment 
and substrate recognition [100, 138]. To determine the roles of these domains in IL-17 
signaling, A20-/- MEFs were reconstituted with either WT A20, or the OTU domain and ΔZnF4-
5 mutants (Figure 3.9-A). Twenty-four hours later, cells were stimulated with IL-17 and 
supernatants evaluated for IL-6 by ELISA. Neither mutant inhibited IL-17-dependent IL-6 
secretion as effectively as WT A20 (Figure 3.9-B). Similarly, neither mutant exerted detectable 
suppression on Il6 mRNA expression (Figure 3.9-B). Although in some experiments the OTU 
mutant mediated a mild suppressive effect (Figure 3.9-B), this was not always reproducible 
(Figure 3.9-C), and may be due to a higher expression capacity of the mutants in comparison to 
WT A20 (Figure 3.9-D). To further confirm the role of both OTU and ZnF domains, we 
reconstituted A20-/- MEFs with a construct encoding just the terminal four ZnF domains (Figure 
3.9-C); this mutant also failed to inhibit IL-17-induced IL-6 production. Collectively, we 
conclude that A20-mediated inhibition of IL-17 signaling involves both the catalytic OTU 
domain as well as the ZnF domains of this protein.  
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Figure 3.9: Inhibition of IL-17 signaling is mediated through the OTU and zinc finger 
domains of A20. 
(A) Schematic diagram of A20 subdomains. OTU = DUB domain. Location of zinc fingers 
(ZnF) is shown. (B) ZnF mutants of A20 impair its ability to regulate IL-17 signaling. A20-/- 
cells were transfected in triplicate with EV, A20 or the indicated mutants and treated with IL-17 
for 4 hours. IL-6 in culture supernatants was assessed by ELISA in triplicate (top), and 
expression of Il6 mRNA was assessed by qPCR. * P <0.05 by ANOVA and post-hoc Tukey’s 
test compared to samples transfected with EV and treated with IL-17.  ‡ P < 0.05 by ANOVA 
and post-hoc Tukey’s test compared to samples transfected with A20 and treated with IL-17.  
(C) A20-/- MEFs were transfected with the indicated A20 mutants, treated with IL-17 for 24 
hours and IL-6 measured by ELISA in triplicate. *P < 0.05 by ANOVA and post-hoc Tukey’s 
test. (D) Expression of A20 mutants. Lysates from A20-/- cells transfected with the indicated 
A20 mutants were blotted for Flag to detect A20 (top) or β-tubulin (bottom). Arrows indicate 
migration of individual A20 mutants. NS, nonspecific band. 
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3.2.8 A20 associates with IL-17RA independently of the receptor SEFIR domain.  
IL-17RA contains several functional subdomains (Figure 3.10-A). Therefore, we asked whether 
A20 interacts directly with IL-17RA, thereby inhibiting the signaling pathway. To determine if 
IL-17RA and A20 interact, HEK293T cells were co-transfected with A20 and murine IL-17RA 
(tagged at the C-terminus with Myc). Lysates were immunoprecipitated with anti-Myc Abs to 
pull down the IL-17 receptor, and association with A20 was determined by western blotting. As 
shown, A20 associated with IL-17RA in a dose-dependent manner (Figure 3.10-B). Strikingly, 
this is to our knowledge the first time that A20 has been demonstrated to bind directly to an 
inducing receptor. 
The SEFIR is conserved among IL-17 receptor family members and serves as a platform 
for association with Act1, which in turn interacts with TRAF6 [66]. A large, non-conserved 
extension of the SEFIR, termed a SEFEX, is also required for signaling in response to IL-17 
[33, 57, 99]. A point mutation within the SEFEX (V553H) renders IL-17RA non-functional, 
and impairs activation of both the NF-κB and MAPK pathways [89, 99]. Because A20 restricts 
activation of both NF-κB and MAPK, we initially predicted that the SEFIR/SEFEX region 
would be the site of interaction with A20. Unexpectedly, A20 associated strongly with the IL-
17RA∆SEFIR and IL-17RA.V553H mutants (Figure 3.10-C), indicating that A20 binds to IL-
17RA in a SEFIR/SEFEX-independent manner.  
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Figure 3.10: A20 binds IL-17RA independently of the SEFIR domain.  
(A) IL-17RA binds to A20 in a dose-dependent manner. HEK293T cells were transfected with 
IL-17RA (tagged at the C-terminus with Myc) together with decreasing concentrations of A20 
plasmid (1.5-0.06 µg). Anti-Myc Abs were used to pull down IL-17RA, and 
immunoprecipitates were blotted with A20 (top) or Myc to detect IL-17RA (middle). WCL 
from samples taken prior to IP were blotted for A20 (bottom). (B) Schematic diagram of IL-
17RA mutants. ECD, extracellular domain; locations of SEFIR/SEFEX, point mutants (V553H, 
PSAA) and CBAD domains are indicated. (C) A20 binds to IL-17RA in a SEFIR/SEFEX-
independent manner. HEK293T cells were transfected with IL-17RA (tagged at the C-terminus 
with HA) with A20. Anti-HA Abs were used to pull down IL-17RA, and IPs were blotted with 
A20 (top) or HA to detect IL-17RA (middle).  Expression of A20 in whole cell lysates is 
indicated (bottom). 
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3.2.9 A20 binds to the IL-17RA at the C-terminal inhibitory domain. 
In addition to the SEFIR/SEFEX, a C-terminal domain located downstream of residue 665 and 
non-overlapping with the SEFIR/SEFEX region has been described. This region is required for 
regulation of C/EBPβ, and hence was termed the “C/EBPβ activation domain” (CBAD) [99]. 
To determine whether A20 interacts with the CBAD, A20 was co-expressed with a panel of C-
terminal truncations of IL-17RA. Binding of A20 to IL-17RAΔ800 was reduced compared to 
full length IL-17RA. IL-17RAΔ665 and all the larger truncations were also severely impaired in 
the ability to co-IP with IL-17RA (Figure 3.11).  
The CBAD contains a TRAF binding motif that was reported to be required for its 
interaction with TRAF3 [90]. Therefore, we tested the association of A20 with an IL-17RA in 
the absence of TRAF6 and TRAF3. A20 co-immunoprecipitated with IL-17RA in TRAF6-
deficient cells (Figure 3.12-A), consistent with the lack of a requirement for the SEFIR/SEFEX 
in its recruitment. To determine the role of TRAF3, we used an IL-17RA mutant lacking 
TRAF3 binding site (PSAA). A20 co-immunoprecipitated with the IL-17RA.PSAA mutant 
normally (Figure 3.12-B). We and others have previously shown that the CBAD is an 
inhibitory domain, because IL-17RA truncation mutants lacking this region exhibit enhanced 
IL-17-dependent signaling [33, 89, 90, 99]. Its association with A20 may explain the underlying 
basis for how the CBAD inhibits IL-17 signal transduction.  
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Figure 3.11: A20 binds to IL-17RA through the CBAD domain. 
A20 binds to IL-17RA via the CBAD. HEK293T cells were transfected with IL-17RA (tagged 
at the C-terminus with Myc) with A20. Anti-Myc Abs were used to pull down IL-17RA, and 
IPs were blotted with A20 (top) or Myc to detect IL-17RA (middle). Expression of A20 in 
whole cell lysates is indicated (bottom).  
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Figure 3.12: TRAF6 and TRAF3 are not required for association between IL-17RA and 
A20.  
(A) A20 binds to IL-17RA in a TRAF6-independent manner. TRAF6-/- MEFs were co-
transfected with A20 and Myc-tagged IL-17RA or empty vector (EV). Lysates were 
immunoprecipitated with Abs to Myc and blotted for A20 (top) or Myc (bottom). Whole cell 
lysates (WCL) prior to IP were blotted for A20 (top) or IL-17RA (Myc, bottom). (B) A20 does 
not bind to the CBAD TRAF consensus site. HEK293T cells were transfected with IL-17RA or 
IL-17RA.PSAA (tagged at the C-terminus with HA) together with A20. Anti-HA Abs were 
used to pull down IL-17RA, and IPs were blotted with A20 (top) or HA to detect IL-17RA 
(bottom). 
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3.3 DISCUSSION 
The IL-17 family is the newest and least understood of the cytokine subclasses [18]. Composed 
of ligands IL-17A-IL-17F and receptors IL-17RA-IL-17RE, these cytokines have many unique 
structural and functional features. Since the discovery of the TH17 subset in 2005, considerable 
attention has been paid to how TH17 and other IL-17-producing cells are generated and 
maintained, but far less to how IL-17 mediates downstream signaling [23, 139].  
Although IL-17 is vital for host defense against certain pathogens, it has high potential 
for inducing pathological damage to inflamed tissue. Hence, it is not surprising that there are 
numerous mechanisms in place to constrain IL-17/TH17activity [140, 141]. To list a few 
examples, TH1 and TH2 cytokines (IFNγ and IL-4) and IL-2 block differentiation of Th17 cells 
[21, 22, 142]. Th17 cells often convert to Tregs or TH1-like cells in vivo, tempering their 
inflammatory activity [143-145]. Immunoregulatory cytokines such as IL-25, IL-27 and IL-10 
limit TH17-mediated pathology [60, 146-148]. At the level of the IL-17R signaling pathway, 
TRAF3 was reported to inhibit IL-17 by binding to IL-17RA and displacing Act1 [90]. A recent 
report also implicates miR-23b in limiting IL-17 activity [98]. IL-17-inducible degradation of 
Act1 follows engagement of the receptor, mitigating the signaling response [96]. In studying 
activation of C/EBP transcription factors, we found that IL-17-induced phosphorylation of 
C/EBPβ by GSK-3β exerts a suppressive effect on IL-17 target gene expression [89]. 
Additionally, IL-17A can exist either as a homodimer or as a heterodimer with IL-17F, and in 
the latter state has a reduced signaling capacity that probably moderates its activity in vivo [56, 
149, 150]. A new report identifies the DUB USP25 in targeting TRAF5 and TRAF6 and 
limiting IL-17 signaling [92].  
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Like other inflammatory effectors, IL-17 activates the canonical NF-κB pathway, albeit 
far more modestly than TNFα or TLR ligands [18]. The NF-κB pathway is intricately regulated 
by ubiquitination and deubiquitination [114]. A20 dampens TNFR-induced signaling [124] and 
is the gene product of a well-known susceptibility locus for autoimmunity. The primary 
enzymatic function of A20 is to serve as a DUB, though it can also act as a Ub-ligase and 
inhibit signaling independently of catalytic activity [117, 121, 135, 151]. In the IL-17 pathway, 
both Act1 and TRAF6 are E3 Ub-ligases that target TAK1 and IKKα/β/γ, ultimately causing 
degradation of IκBα and nuclear import of NF-κB [65, 70]. In IL-1 and TLR systems, A20 
limits MAPK activation by targeting TRAF6 [124]. Our work reveals for the first time that A20 
is both a gene target and a potent feedback inhibitor of IL-17 signaling, acting via TRAF6, NF-
κB and MAPK. Therefore, regulation of ubiquitination is emerging as a central feature of IL-17 
signal transduction (Figure 3.13). 
Using RNA silencing and A20-/- cells, we show that a variety of IL-17-induced target 
genes are negatively regulated by A20 (Figure 3.2-3.6). As expected, nearly all these genes are 
regulated by NF-κB, including genes encoding IL-6 and 24p3 where the proximal promoters 
require an intact NF-κB element for their induction by IL-17 [72, 73]. Interestingly, there are 
certain exceptions. For example, Ikbz expression was largely unaffected by A20 (Figure 3.4 
and 3.6). The basis for this difference is not clear; however, IL-17 can also regulate the stability 
of many target mRNAs [152]. Best-studied in the context of the chemokine Cxcl1 (KC, Groα), 
this event is mediated in a non-canonical fashion by activation of the splicing factor (SF) 2 
through TRAF2 and TRAF5 [77]. A20 does not appear to influence mRNA stability, perhaps 
explaining its modest effect on some genes but not others (Figure 3.3 and 3.4). Similar to the 
TNF pathway, A20 also inhibits IL-17-mediated activation of MAPK pathways, particularly Jun 
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kinase (JNK) (Figure 3.8-B). MAPK activation leads to AP-1 activation, and AP-1 DNA 
binding sites are statistically overrepresented in IL-17 target gene promoters [73]; however, at 
least for the Il6 gene promoter, the AP-1 site is dispensable for IL-17 activation [72]. In 
addition, MAPK signaling may participate in regulation of mRNA stability, although it is not 
clear to what extent this is the case for IL-17-dependent genes.  
We found that A20 binds directly to IL-17RA, which is the first time A20 has been 
demonstrated to interact with a cytokine receptor, and supports a direct model of inhibition of 
IL-17 (Figure 3.10). Like most receptors, IL-17RA contains discrete functional subdomains 
[61, 99]. Intriguingly, A20 binds to the distal domain of IL-17RA, not the SEFIR/SEFEX region 
that is the site of engagement for Act1 and TRAF6 [33, 66]. This distal domain was initially 
identified by its ability to regulate C/EBPβ alternative translation and phosphorylation, and 
hence was termed a C/EBPβ activation domain, CBAD [89, 99]. Phosphorylation of C/EBPβ 
via glycogen synthesis kinase (GSK)-3β is mediated through the CBAD and is associated with 
dampened IL-17R signaling [89]. A TRAF consensus site within the CBAD is an interaction 
site for TRAF3 (but not TRAF6), which was reported to inhibit IL-17 by competing with Act1. 
Here, we show that A20 also binds the CBAD, although not via the TRAF consensus site 
(Figure 3.11 and 3.12), indicating that the CBAD may serve as a platform for binding of 
multiple inhibitory proteins.  
There are still many open questions regarding the details of how A20 restrains IL-17 
signaling. In other systems, A20 cooperates with Itch, TAX 1 binding protein 1 (TAX1BP1) 
and RNF11 to form a functional ubiquitin-editing complex [120], but it is not known whether 
any/all of these factors are required to inhibit IL-17R signaling. It is also not known whether 
A20 blocks other IL-17 family ligands that signal via IL-17RA, such as IL-17E (IL-25) or IL-
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17C. Since IL-17 has repeatedly been shown to use non-canonical pathways and signaling 
intermediates, it is likely that surprises will emerge regarding how this pathway is controlled. 
The human A20 gene locus, TNFAIP3, is strongly associated with many autoimmune 
diseases. Clearly this is related in part through A20 inhibition of TNF [153]. However, A20 also 
constrains TLR and NLR signaling, which are increasingly recognized as important in 
mediating autoimmunity [154, 155]. We now add IL-17 to the list of pro-inflammatory 
pathways governed by A20. This finding dovetails well with the role for IL-17 in mediating at 
least some forms of autoimmune disease, as illustrated by the clinical success of biologic 
therapies targeting this cytokine [27]. Consistently, silencing of A20 led to enhanced IL-17 
signaling in human rheumatoid arthritis FLS cells (Figure 3.4-B), supporting the potential 
relevance of A20 in human cells. Nonetheless, more work is certainly needed to determine how 
much of A20’s impact on IL-17 contributes to disease in vivo compared to other inflammatory 
stimuli.  Defining molecular signaling intermediates, especially enzymes such as A20, has the 
potential to reveal strategies for developing small molecule therapeutics that target IL-17 [156, 
157]. Drugs that enhance A20 function could theoretically help restrain IL-17 and other 
inflammatory cytokines that promote autoimmunity (discussed in Chapter 6); alternatively, 
blocking A20 might be useful in stimulating host defenses to settings where IL-17 activity is 
beneficial, such as fungal and bacterial infections [31]. 
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Figure 3.13: Schematic diagram of IL-17RA-mediated signaling, and role of A20 in 
restricting this process. 
A20 serves as a feedback inhibitor of IL-17 signaling by restricting TRAF6 ubiquitination and 
subsequent NF-κΒ and MAPK activation. A20 directly associates with the IL-17RA CBAD 
domain, suggesting a model where IL-17RA recruits inhibitory proteins to the distal C-terminal 
domain. 
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4.0  CHAPTER FOUR: THE ANAPHASE-PROMOTING COMPLEX PROTEIN 5 
(ANAPC5) ASSOCIATES WITH A20 AND INHIBITS IL-17 SIGNALING 
This is the author's adaptation of the work published in Journal, 
PLOS ONE, July 2013, Volume 8, Issue 7, e70168 
‘The Anaphase-Promoting Complex Protein 5 (AnapC5) Associates with A20 and Inhibits 
IL-17-Mediated Signal Transduction’ 
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4.1 BACKGROUND 
Multiple proteins are involved in the regulation of IL-17 signal transduction and have been 
described in detail earlier (Chapter 1). Here we focus our attention on the inhibition of IL-17 
receptor signaling. The IL-17 signaling pathway is kept in check by a variety of downstream 
inhibitors, which help limit collateral damage in settings of acute infection. To list a few 
examples, Act1 is inducibly degraded following receptor stimulation by the Skp-Cullin1-F box 
(SCF)-βTrCP complex [155]. MiR-23b blocks IL-17 signaling by targeting the NF-κB pathway 
and IκBζ, and is associated with several autoimmune diseases [98]. NF-κB activation is 
dampened by reversing ubiquitination of TRAFs, and in this regard, a DUB, USP25, was 
recently implicated in restricting the IL-17 pathway [92, 158]. Additionally, we described 
another deubiquitinase, A20, which acts by removing ubiquitin chains from TRAF6 (Chapter 
3, [158]). While USP25 activity appears thus far to be limited to the TLR and IL-17 pathways 
[92, 159], A20 restricts NF-κB activation by TNFR, IL-1R, Nod-like receptors and TLRs as 
well as IL-17R [85]. 
In the TNFα, LPS and IL-1β signaling pathways, adaptor proteins such as TAX1BP1, 
Itch and RNF11, provide essential assistance to A20 [85, 117, 160]. In response to these 
inflammatory signals, TAX1BP1, Itch and RNF11 inducibly interact to form the A20 ubiquitin-
editing complex [160]. Similar to A20-/- cells, cells lacking TAX1BP1, Itch or RNF11 exhibit 
persistent activation of NF-κB in response to inflammatory stimuli [161]. Although it is unclear 
what regulates the inducible interactions among A20, TAX1BP1, Itch and RNF11, the 
association of these proteins is critical for the termination of NF-κB signaling. Recent reports 
have shed some light into the individual roles of these proteins. For example, TAX1BP1 is 
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considered a ubiquitin-binding adaptor molecule for A20 [162]. This finding suggests a model 
where TAX1BP1 recruits K63-ubiquitinated proteins (TRAF6, RIP1) to the A20-TAX1BP1 
complex and aids the deubiquitination function of A20 [163]. Similarly, in response to TNFα 
and LPS stimulation, Itch and RNF11 bind to the A20-TAX1BP1 complex and assist in A20-
mediated NF-κB and MAPK inhibition [160, 164]. In addition to TNFα, TLR and IL-1β, A20 
also inhibits IL-17 signaling (Chapter 3). Therefore, we hypothesized that TAX1BP1 and Itch 
were required for A20-mediated inhibition of IL-17 receptor signaling. 
Efforts to decipher signaling events downstream of the IL-17 receptor have largely 
focused on the IL-17RA subunit. However, IL-17RC also confers essential, but poorly 
understood, signaling properties [58]. Mutants of IL-17RC lacking the cytoplasmic tail, 
especially the SEFIR domain, fail to rescue signaling in an IL-17RC-deficient setting [55, 57]. 
Accordingly, a previous graduate student in the Gaffen laboratory, Allen Ho, performed a yeast-
two hybrid screen to identify novel signaling intermediates that bind to IL-17RC [165]. The 
murine IL-17RC cytoplasmic domain was used as bait in order to screen for proteins that 
associated with this domain.  One of the most frequent binding candidates was the anaphase 
promoting complex protein 7 (AnapC7, also known as APC7). Intriguingly, AnapC7 has never 
been previously associated with an inflammatory signaling pathway. In fact, the only described 
role of AnapC7 is in the Anaphase Promoting Complex (APC), as an adaptor protein. APC is a 
multi-protein E3 ubiquitin ligase that triggers the transition from metaphase to anaphase. APC 
regulates eukaryotic mitotic progression by targeting proteasomal degradation of specific 
proteins such as securin [166]. AnapC7 is a vertebrate-specific subunit of the APC [167]. 
Although AnapC7 itself does not possess enzymatic function, it is essential for APC activity. In 
addition to regulating APC progression, AnapC7 been shown to interact with the transcriptional 
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coactivators CBP and p300 and stimulate their transcriptional activity [168]. AnapC7 and its 
structurally and functionally related APC complex proteins, AnapC5 and AnapC3, contain 
multiple tetratrico peptide repeat (TPR) motifs that mediate the binding of adaptor protein 
CDH1 [167, 169-171]. Recruitment of CDH1 and other AnapC complex proteins is essential for 
the proper functioning of the APC [166]. The role of AnapC7 in the recruitment of APC 
subunits indicates that AnapC7 could potentially act as an adaptor protein in inflammatory 
pathways such as IL-17. Therefore, I chose to further analyze AnapC7 as a potential adaptor in 
the IL-17R signaling pathway. 
 Surprisingly, we found that neither TAX1BP1 nor Itch appear to participate in the IL-17 
receptor pathway. Moreover, AnapC7 showed no detectable impact on IL-17 receptor signaling. 
However, we detected association of AnapC7 with both IL-17 receptor subunits (IL-17RA and 
IL-17RC). Therefore, we tested a closely related APC subunit, AnapC5 for a potential role in 
IL-17 signaling. AnapC5 was also able to bind IL-17RA and IL-17RC, and AnapC5 silencing 
enhanced IL-17-induced gene expression, suggesting an inhibitory activity. Strikingly, AnapC5 
could also bind to A20 and interact with IL-17RA in the same receptor subdomain that binds to 
A20 [158]. Therefore, these data suggest a new model in which AnapC5 participates in IL-17 
receptor signal transduction by forming a complex with the inhibitor A20.  
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4.2 RESULTS 
4.2.1 The A20 accessory molecules Itch and TAX1BP1 are not involved in inhibitory IL-
17 signaling. 
Accessory molecules such as TAX1BP1 and Itch associate with A20 to form an active 
inhibitory complex in the TNFR and IL-1/TLR signaling cascades [120]. Given the negative 
regulatory role of A20 in the IL-17R signaling pathway, we investigated whether TAX1BP1 
and Itch were required for IL-17-mediated inhibitory signaling. Surprisingly, knockdown of 
TAX1BP1 and Itch expression with siRNA revealed no significant modulation in IL-17-
dependent expression of Il6 or Ccl20 mRNA levels, as measured by qPCR. Similar findings 
were made for additional IL-17 target genes, including Ikbz and cxcl1, though we observed very 
modest enhancements in these genes upon knockdown of TAX1BP1 and Itch (Figure 4.1-A). 
The efficiency of TAX1BP1 and Itch knockdown was high, as confirmed by qPCR (Figure 4.1-
B). These data suggest that the A20 accessory molecules TAX1BP1 and Itch are dispensable for 
the negative regulatory functions of A20 downstream of IL-17. 
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Figure 4.1: The A20 accessory molecules Itch and TAX1BP1 are not involved in inhibitory 
IL-17 signaling. 
(A) Knockdown of Itch and TAX1BP1 does not impact IL-17R mediated signaling. ST2 cells 
were transfected with the indicated siRNAs, stimulated with IL-17 for 24 h, and mRNA 
expression was assessed by qPCR. (B) Efficient knockdown of Itch and TAX1BP1. mRNA 
from the samples in panel B were assessed for Itch and TAX1BP1 expression by qPCR. n.s., not 
significant. *p<0.05 by ANOVA and post-hoc Tukey’s test compared to mock-transfected 
controls. ‡ p<0.05 by Chi Square comparing experimental replicates. These experiments were 
conducted in collaboration with Lauren Kinner. 
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4.2.2 AnapC7 associates with the IL-17 receptor subunits but is dispensable for IL-17-
dependent signaling. 
To determine whether AnapC7 associated with IL-17RC or other IL-17R subunits, HEK293T 
cells were co-transfected with AnapC7 (HA-tagged) together with full length IL-17RA and IL-
17RC (Myc-tagged) or a panel of receptor truncation mutants, and their ability to interact was 
evaluated by co-immunoprecipitation. AnapC7 associated with IL-17RC, confirming the yeast-
two hybrid result. AnapC7 associated with IL-17RC mutants truncated at the C-terminal end of 
the SEFIR domain (Figure 4.2-A,B), suggesting that the association of AnapC7 with IL-17RC 
occurs somewhere within the conserved SEFIR domain. AnapC7 also associated with full-
length IL-17RA. However, a deletion of IL-17RA lacking the C-terminal “CBAD” domain 
abrogated this association (Figure 4.2-A,B). Thus, AnapC7 interacts with both IL-17RA and 
IL-17RC. 
There are no available AnapC7 knockout mice. To determine whether AnapC7 plays a 
role in IL-17R signaling, we silenced AnapC7 expression via siRNA knockdown in ST2 cells.  
Knockdown of AnapC7 had no impact on IL-17-dependent IL-6 production at the mRNA or 
protein levels (Figure 4.2-C).  As a control, we verified that siRNA silencing of Act1, a 
positive mediator of IL-17 signaling, reduced IL-17 signaling, as measured by IL-6 production. 
As expected, silencing of the DUBs A20 or USP25, recently shown to be inhibitors of IL-17 
signaling [92, 158], resulted in enhanced IL-17-mediated IL-6 production (Figure 4.2-C). 
These results demonstrated that, while AnapC7 associates efficiently with the IL-17 receptor 
complex, its activity is dispensable for functional IL-17-mediated signaling, either positively or 
negatively. 
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Figure 4.2: AnapC7 binds to IL-17R but does not impact IL-17 signaling.  
(A) Schematic diagram of IL-17RA and IL-17RC mutants. ECD, extracellular domain. SEFIR 
and SEFEX domain approximate boundaries are indicated [61, 99]. CBAD, C/EBPβ activation 
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domain. (B) AnapC7 associates with IL-17RA and IL-17RC. HEK293T cells were transfected 
with AnapC7 tagged with HA and IL-17RA or IL-17RC tagged with Myc, as indicated. Lysates 
were immunoprecipitated with anti-Myc Abs and immunoblotted for HA or Myc. Whole cell 
lysates (WCL) were verified for AnapC7 by staining with anti-HA. Migration of protein size 
markers is indicated.  (C) RNA silencing of AnapC7 does not alter IL-17-dependent signaling. 
ST2 cells were transfected with the indicated siRNAs, treated with IL-17 (black bars) for 24 h 
and IL-6 in culture supernatants assessed by ELISA. n.s., not significant. *p<0.05 by ANOVA 
and post-hoc Tukey’s test relative to unstimulated controls.  ‡ p<0.05 by Chi Square comparing 
experimental replicates.   
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4.2.3 AnapC5 associates with IL-17RA through the receptor CBAD domain and 
negatively regulates IL-17 receptor signaling. 
AnapC5 is another structural component of the APC/C. Like AnapC7, AnapC5 also activates 
the cAMP response element-binding protein (CREB) binding protein (CBP)/p300 complex 
[168]. Because of the analogous roles played by AnapC5 and AnapC7 in CBP/p300 regulation 
and the presence of common structural motifs in both proteins, we hypothesized that AnapC5 
might participate in IL-17R signaling. To determine whether AnapC5 associated with the IL-17 
receptor, HEK293T cells were co-transfected with AnapC5 and IL-17RA or IL-17RC, and 
interactions between these factors were evaluated by co-IP.  AnapC5 associated efficiently with 
IL-17RA and IL-17RC ((Figure 4.3-A), lanes 5-6). We further verified that AnapC5 also 
associated with AnapC7 ((Figure 4.3-A), lane 8). Thus, both AnapC5 and AnapC7 form a 
complex with the IL-17 receptor.  
We then sought to delineate motifs within the IL-17R required for interaction with 
AnapC5. HEK293T cells were co-transfected with AnapC5 and a panel of IL-17RA truncation 
mutants. AnapC5 associated only with full-length IL-17RA and to a lesser extent IL-
17RA∆800, but not with other deletion mutants despite equivalent expression of the receptor 
mutants (Figure 4.3-B). Thus, AnapC5 associates with a C-terminal domain of IL-17RA. This 
domain corresponds to the CBAD [89, 99], which has been previously linked to inhibitory 
signaling [89, 90, 99, 158]. We also attempted to define regions within the IL-17RC 
cytoplasmic tail necessary for co-association using a panel of IL-17RC truncation mutants. 
AnapC5 co-immunoprecipitated with all IL-17RC deletion mutants tested, suggesting that the 
site of interaction is within the SEFIR domain (Figure 4.3-C). 
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To determine whether the association of AnapC5 with IL-17RA/C impacted IL-17 
signaling, we employed siRNA to silence AnapC5 in ST2 cells (Figure 4.4-A).  When 
compared to cells transfected with a control siRNA, knockdown of AnapC5 resulted in 
significantly increased IL-17-dependent IL-6 expression (Figure 4.4-A), suggesting that 
AnapC5 exerts an inhibitory function. Similar findings were made for Il6 mRNA (data not 
shown). Silencing efficiency was verified by qPCR (Figure 4.4-B). These findings indicated 
that AnapC5 binds to the IL-17R and dampens IL-17-mediated signal transduction. 
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Figure 4.3: AnapC5 binds to the IL-17RA CBAD domain. 
(A) AnapC5 associates with IL-17RA, IL-17RC and AnapC7. HEK293T cells were transfected 
with AnapC5 (tagged with HA) together with IL-17RA, IL-17RC or AnapC7 (tagged with 
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Myc), as indicated. Lysates were subjected to IP with anti-Myc Abs and immunoblotted with 
anti-HA or anti-Myc. Arrows indicate identity of each Myc-tagged protein. Whole cell lysates 
(WCL) were verified for AnapC7 by staining with anti-HA. Migration of protein size markers is 
indicated. (B) AnapC5 associates with IL-17RA through the inhibitory CBAD domain. 
HEK293T cells were transfected with AnapC5 and the indicated IL-17RA deletion constructs. 
Lysates were subjected to co-IP with anti-Myc and blotted for HA or Myc. Whole cell lysates 
(WCL) were verified for AnapC7 by staining with anti-Myc. Migration of protein size markers 
is indicated. (C) AnapC5 associates with IL-17RC in the SEFIR domain. HEK293T cells were 
transfected with AnapC5 and the indicated IL-17RC deletion constructs. Lysates were subjected 
to co-IP with anti-Myc and blotted for HA or Myc. Whole cell lysates (WCL) were verified for 
AnapC7 by staining with anti-HA. Migration of protein size markers is indicated. These 
experiments were conducted in collaboration with Leticia Monin. 
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Figure 4.4: AnapC5 restricts IL-17-mediated signal transduction.  
(A) Knockdown of AnapC5 enhances IL-17 signaling. ST2 cells were transfected with the 
indicated siRNAs, stimulated with IL-17 for 24 h, and IL-6 in culture supernatants assessed by 
ELISA. (B) Efficient knockdown of AnapC5 and AnapC7. mRNA from the samples in panel D 
were assessed for AnapC5 and AnapC7 expression by qPCR. n.s., not significant. *p<0.05 by 
ANOVA and post-hoc Tukey’s test compared to unstimulated controls. ‡ p<0.05 by Chi Square 
comparing experimental replicates.   
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4.2.4 AnapC5 directly associates with A20. 
Our recent data implicated the DUB A20 as a negative regulator of IL-17-dependent signaling, 
which binds to the CBAD within IL-17RA [33, 89, 90, 99]. Since AnapC5 associated with the 
CBAD and knockdown of AnapC5 enhanced IL-17 signaling, we hypothesized that AnapC5 
might interact with A20. To test this hypothesis, A20 was co-transfected with AnapC5 (both the 
long and short forms of the gene) and AnapC7. As shown, A20 indeed co-immunoprecipitated 
with AnapC5, but not with AnapC7 (Figure 4.5-A), potentially explaining the failure of 
AnapC7 knockdown to impact IL-17 signaling. These data are also consistent with the binding 
of AnapC5 to the CBAD, which is associated with negative regulation of IL-17 signaling 
(Chapter 3, Section 4.3). To verify this finding in a more physiological setting, we transfected 
HEK293T cells with AnapC5 constructs and saw co-immunoprecipitation of endogenous A20, 
while there was no precipitation with a control plasmid (Figure 4.5-B). Thus, AnapC5 
associates with A20 and may facilitate the inhibitory functions of A20 downstream of the IL-
17R (Figure 4.6). Cumulatively, these findings suggest that AnapC5, but not TAX1BP1 or Itch, 
may serve as an accessory protein for A20 in IL-17 signal transduction.   
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Figure 4.5: AnapC5 directly associates with A20. 
(A) AnapC5 but not AnapC7 associates with A20. HEK293T cells were co-transfected with 
AnapC5 [short (s) and long (l) forms] or AnapC7 (both Myc-tagged) together with A20. Lysates 
were subjected to IP with anti-Myc Abs and blotted for A20 or Myc. WCL were blotted for 
A20. Migration of protein size markers is indicated. (B) AnapC5 associates with endogenous 
A20. HEK293T cells were transfected with Myc-tagged AnapC5. Lysates were subjected to IP 
with anti-Myc Abs and blotted for A20 or Myc. WCL were blotted for β-tubulin as a loading 
control. These experiments were conducted by Allen Ho.  
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4.3 DISCUSSION 
IL-17 has emerged as a critical inflammatory cytokine involved in both host defense and 
autoimmune pathology. IL-17 promotes disease in a variety of mouse models of disease 
including multiple sclerosis, RA and IBD [20, 172-174]. Consequently, the IL-17 family is an 
appealing biological target that shows efficacy in early clinical trials [175]. On the host side, IL-
17 is important for immunity to extracellular pathogens, most strikingly those of fungal origin 
such as Candida albicans [108, 176].  
Efforts to understand the IL-17 signaling pathway have lagged behind other cytokine 
families. Superficially, IL-17 appears to share many of the same pathways and gene targets as 
other pro-inflammatory cytokines; for example, engaging the NF-κB and MAPK pathways and 
inducing expression of canonical inflammatory mediators such as IL-6 and CXC chemokines 
[18, 65]. However, IL-17R structure and signaling are atypical in multiple ways. The three-
dimensional architecture of IL-17 family receptor and ligands are distinct from other cytokines 
[15, 177, 178]. The proximal adaptor Act1, required for NF-κB signaling, is not employed as a 
positive signaling intermediate by any other known inflammatory signaling pathway [115]. 
Similarly, the means by which IL-17 promotes stability of target mRNA transcripts is unusual, 
involving the Splicing Factor 2 (SF2) RNA binding protein rather than the more classical 
tristetraprolin protein [53, 152].   
Polymorphisms in the gene encoding A20 (TNFAIP3) are implicated in various forms of 
autoimmunity and some cancers [85, 179]. A20 is a deubiquitinase (DUB) that serves as a 
negative feedback inhibitor of TNFα, IL-1, and IL-17 [85, 158]. A20 acts on the IL-17 
signaling pathway by down-modulating the NF-κB and MAPK pathways through 
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deubiquitination of TRAF6 [119, 158]. In addition to its activity as a DUB, A20 also exhibits 
Ub ligase activity [135], which helps dictate the types of Ub linkages used to modulate 
signaling. In TNFα, IL-1β and TLR signaling, TAX1BP1, Itch and RNF11 are vital for A20 
activity [160, 161]. However, the A20-accessory proteins Itch and TAX1BP1 had no apparent 
role in inhibiting IL-17-mediated signaling in my studies (Figure 4.1). Although this does not 
absolutely rule out a role for either factor in the IL-17 signaling pathway, they do not seem to be 
critical players. Moreover, we did not analyze whether RNF11 is involved in the regulation of 
IL-17 signaling, which would be important to test in the future. Finally, as IL-17 synergizes 
with TNFα and IL-1β, TAX1BP1, Itch and RNF11 might still have an effect on the synergistic 
target gene expression by these other cytokines. 
We also examined the role of AnapC7, one of the most frequent “hits” yielded in the 
two hybrid screen, in regulating IL-17 signal transduction. AnapC7 is best understood as a 
component of a macromolecular E3 ubiquitin ligase complex required for mitotic progression 
[167]. AnapC7 is also implicated in regulating gene transcription by interacting with the 
CBP/p300 coactivator and stimulating its acetyl transferase activity [168]. Although AnapC7 
interacted with IL-17RA and IL-17RC, knockdown of AnapC7 exerted no apparent impact on 
IL-17 signaling, either positively or negatively (Figure 4.2). On the other hand, knockdown of 
AnapC5 enhanced IL-17 dependent signaling, suggesting that it might function as an inhibitor 
of the pathway (Figure 4.4). AnapC7 and AnapC5 share sequence homology with E1A, an 
adenoviral protein that drives cellular transformation via CPB/p300 complexes. The present 
work is to our knowledge the first evidence implicating AnapC5 as a signaling intermediate for 
cytokine receptor signaling. 
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A20 binds to IL-17RA through a distal inhibitory domain in the receptor known as the 
“CBAD,” a domain originally identified based on its role in regulation of the C/EBPβ 
transcription factor [89, 99]. Since AnapC5 is part of a multi-protein E3 Ub ligase complex and 
also binds to the CBAD (Figure 4.3), we speculated that its ability to inhibit IL-17 signaling 
might be regulated through A20. Indeed, A20 interacted strongly with AnapC5, but not with 
AnapC7 (Figure 4.5). Together, these data raised the possibility that the AnapC5 is part of a 
novel inhibitory complex that includes A20 and that assembles on the IL-17R CBAD domain 
(Figure 4.6).  
It is unclear what role, if any, is played by AnapC7 in IL-17 signaling. Unlike AnapC5, 
silencing of AnapC7 did not impact IL-17 induction of genes such as Il6.  One possibility is that 
AnapC7 acts as a scaffold protein for as-yet unidentified factors that mediate signal transduction 
specificity by IL-17RC (Figure 4.6). In this regard, the role of the IL-17RC cytoplasmic tail in 
IL-17R signaling is still unresolved. Deletion studies indicate that the IL-17RC tail is essential 
[55, 57], so the receptor is evidently needed for more than just engaging the ligand. We 
previously showed that a dimer of the IL-17RC tail is insufficient to mediate signaling; namely, 
a chimeric receptor composed of the extracellular and transmembrane domain of IL-17RA fused 
to the cytoplasmic tail of IL-17RC could not rescue signaling in IL-17RA-deficient cells [33]. 
However, it is not known whether IL-17RC recruits novel proteins into the IL-17R signaling 
complex, or whether this subunit is simply needed to multimerize or stabilize existing signaling 
complexes by providing additional binding sites for proteins such as Act1 or the AnapCs.   
There are important questions raised by this study that will need to be explored in future 
studies. For example, what are the relative contributions of A20, βTrCP1 and USP25 on 
inhibition of IL-17 signaling? Are they redundant, cooperative or do they play tissue-specific 
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roles? Does AnapC5 serve as a “switch” to favor one inhibitory pathway over the other? How 
important is the interaction of AnapC5 in binding to IL-17RC versus IL-17RA? Ultimately, 
defining the molecular events in the IL-17R pathway may yield new therapeutic targets, and 
will certainly provide new insights into how this intriguing cytokine receptor family operates. 
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Figure 4.6: Schematic model of AnapC5 and AnapC7 in IL-17R signaling.  
The data discussed above support a model in which AnapC5 serves an adaptor or scaffold 
protein to facilitate A20 recruitment to the CBAD domain of IL-17RA.  Although AnapC7 
binds to both IL-17RA and IL-17RC, its functional role is still unclear.  
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5.0  CHAPTER FIVE: MCPIP1 (REGNASE-1) INHIBITS IL-17 SIGNALING BY 
MEDIATING DEGRADATION OF IL-17 RECEPTOR TRANSCRIPT  
 94 
5.1 BACKGROUND 
Proinflammatory cytokines such as IL-17 exert their function by inducing expression of 
inflammatory cytokines and chemokines. Additionally, inflammatory signaling pathways switch 
on expression of proteins that act as feedback inhibitors of these pathways. For example, A20 
and miR-23b expression are regulated by IL-17, and these molecules act as feedback inhibitors 
of IL-17 pathway [98, 158].  Therefore, in line with our interest in elucidating inhibitory 
mechanisms of IL-17 pathway, we aimed to identify novel physiologically relevant feedback 
inhibitors of IL-17 signaling. To this end, we mined previously published microarray data 
comparing the gene expression profiles in WT and IL-17RA-/- mice infected orally with C. 
albicans, a setting in which IL-17RA-/- mice are susceptible to disease [28]. We screened for the 
genes that were induced more strongly in WT mice than in IL-17RA-/- mice. Through this 
screen, we identified Zc3h12a (Zinc Finger CCCH-type containing 12A) as an IL-17-
induced gene. Zc3h12a encodes a protein called MCPIP1 (Monocyte Chemotactic Protein-1 
Induced Protein-1, also known as Regnase-1) that had previously shown to inhibit TLR and IL-
1R signaling [101, 180]. Therefore, we decided to assess whether MCPIP1 is involved in the 
regulation of IL-17R signaling. 
MCPIP1 is expressed constitutively in most cells types, including both immune cells 
(particularly T cells) and non-immune cells. Furthermore, MCPIP1 expression is upregulated by 
several cytokines and inflammatory stimuli, including MCP-1, IL-1β and LPS [181]. MCPIP1 
belongs to a family of proteins (MCPIP1 through MCPIP4) that contain a highly conserved 
Nedd4-BP1, YacP Nuclease (NYN) domain with RNase activity at the N-terminus and a single 
CCCH-type zinc finger domain with RNA-binding potential in the intervening region [182-
184]. Other examples of CCCH-type zinc finger proteins include tristetraprolin (TTP). TTP was 
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the first identified CCCH-type zinc finger protein and acts as an RNA destabilizing agent by 
binding to the adenylate-uridylate-rich (AU-rich) elements (AREs) in mRNA to increase RNA 
turnover [185, 186]. Through this activity, TTP regulates the expression of multiple cytokines 
and chemokines such as TNFα, IL-1 and CXCL1. However, studies so far suggest that IL-17 
signaling employs TTP-independent mechanisms to regulate mRNA stability [77]. 
Like other CCCH-type zinc finger proteins, MCPIP1 is an RNase that inhibits 
inflammatory cytokine expression by degrading Il6, Il1b and Il12b (p40) mRNA [183]. The 
RNase activity of MCPIP1 is dependent on its CCCH-type zinc finger domain of MCPIP1, 
which includes three cysteine residues and one histidine residue. The zinc finger coordinates 
zinc ion binding, which is necessary for RNA-binding capacity of MCPIP1. MCPIP1 catalytic 
function also depends on Mg2+ ion binding. The crystal structure of the N-terminal RNase 
domain of human MCPIP1 as well as MCPIP1 point mutant studies revealed a catalytic pocket 
composed of several conserved acidic amino acids, including several aspartate residues that are 
involved in Mg2+ ion binding [101, 183, 184, 187]. 
MCPIP1 inhibits LPS, IL-1β and TNFα signaling by degrading Il6 and Il12b mRNA and 
restricting ensuing inflammation [180, 183, 188]. MCPIP1 also suppresses miRNA biosynthesis 
and activity via cleavage of the terminal loops of precursor miRNAs (pre-miRNAs) and 
inhibiting DICER activity [187]. Additionally, MCPIP1 inhibits LPS, IL-1β and TNFα-
mediated NF-κB and c-Jun N-terminal kinase (JNK) activation by deubiquitinating TRAFs, 
including TRAF2, TRAF3 and TRAF6 [101]. Thus, by regulating mRNA decay of 
inflammatory proteins as well as through its DUB activity, MCPIP1 potently suppresses 
aberrant activation of innate and adaptive immune cells. 
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Consistent with a critical role for MCPIP1 in regulating inflammation, mice lacking 
MCPIP1 (MCPIP1-/-) display severe systemic inflammation characterized by abnormal T cell 
and B cell activation. Furthermore, these mice show hyperimmunoglobulinemia, autoantibodies, 
growth retardation, and die prematurely [101, 183]. Systemic inflammation in MCPIPI-/- mice 
has been attributed to the lack of regulation in both immune and non-immune compartments 
[189-191]. In T cells, MCPIP1 is expressed constitutively and prevents spontaneous activation 
of T cells. In addition to degrading Il6 and Il12b mRNA, MCPIP1 also targets degradation of 
mRNA transcripts that encode key proteins involved in T-cell activation. For example, in T 
cells, MCPIP1 degrades mRNAs encoding c-Rel, IL-2, OX40 and ICOS [190]. As a result, mice 
lacking MCPIP1 specifically in T cells are unable to dampen spontaneous T-cell activation, 
therefore contributing to autoimmune symptoms. Additionally, MCPIP1-mediated regulation of 
TLR signaling is also relevant in controlling autoimmune inflammation. MCPIPI-/- mice treated 
with antibiotics to eradicate commensal microbial flora were found to have both better survival 
and reduced inflammation in spleen and lymph nodes [189]. As previously stated, we found that 
MCPIP1 expression is also induced by IL-17. Additional reports have confirmed induction of 
Zc3h12a expression by IL-17 in an Act1-dependent manner [75, 192]. However, whether 
MCPIP1 regulates IL-17R signaling has not been determined.  
In this study, we demonstrate that MCPIP1 is a negative regulator of IL-17R signaling. 
We discovered that Il17ra and Il17rc mRNA are degraded by MCPIP1, revealing a novel target 
for MCPIP1. Furthermore, lack of MCPIP1 in mice resulted in enhanced IL-17 induced 
pulmonary inflammation, better control of disseminated C. albicans infection and increased 
severity of EAE. Therefore, we establish that MCPIP1 is a critical modulator of IL-17 induced 
inflammation. 
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5.2 RESULTS 
5.2.1 MCPIP1 inhibits IL-17 signaling. 
Multiple inflammatory stimuli including LPS, IL-1β, MCPI-1 and IL-17 induce expression of 
Zc3h12a (encoding MCPIP1) [192, 193]. To confirm that Zc3h12a is an IL-17 target gene, we 
stimulated ST2 cells with IL-17 over a time course of 24 hours, and determined relative 
Zc3h12a expression by qPCR. We detected an increased expression of Zc3h12a mRNA over 
baseline as early as 15 minutes after IL-17 stimulation. Zc3h12a mRNA expression peaked at 
approximately 7-fold within one hour and stayed elevated up to 24 hours (Figure 5.1-A). The 
kinetics of Zc3h12a expression are different from Tnfaip3 expression, which peaks within 30 
minutes (10-15 fold over baseline) of IL-17 stimulation, drops rapidly and stabilizes at a lower 
level (4-5 fold over baseline) (Figure 3.2A) [158].  
MCPIP1 is a feedback inhibitor of inflammatory receptor signaling pathways such as 
TLR and IL-1R [101, 181]. Therefore, we hypothesized that MCPIP1 is also an inhibitor of IL-
17R signaling. To assess the function of MCPIP1 in IL-17 signaling, ST2 cells were transfected 
with siRNA targeting MCPIP1 or control non-targeting scrambled siRNA. siRNA targeting 
Act1, an essential adaptor protein in IL-17R signaling, was used as a positive control. Forty-
eight hours after transfection, cells were stimulated with IL-17 for three hours and IL-6 protein 
levels and mRNA transcript expression were measured by ELISA and qPCR, respectively. As 
expected, cells transfected with control siRNA exhibited increased IL-6 protein and mRNA 
expression after IL-17 stimulation, whereas Act1-targeting siRNA led to a significant drop in 
IL-17-dependent IL-6 expression. Interestingly, we observed that the cells transfected with 
siRNA targeting MCPIP1 exhibited an increase in baseline IL-6 expression, pointing to an 
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important role of MCPIP1 in regulating basal inflammatory cytokine expression. However, IL-
17 stimulation in these cells resulted in a further significant increase in IL-6 protein and mRNA 
expression (Figure 5.1-B,C). To confirm the function of MCPIP1 in regulating IL-17 signaling, 
we tested the effect of MCPIP1 knockdown on other IL-17 target genes. As expected, MCPIP1 
knockdown resulted in a significant increase in IL-17-dependent expression of lcn2 and csf3. 
Finally, we verified that the siRNA targeting MCPIP1 efficiently reduced Zc3h12a expression 
(Figure 5.2-C).  
To rule out possible off-target effects of the siRNA, we reconstituted mouse MCPIP1 
knockout tail tip fibroblasts with either empty vector (EV) or plasmid expressing MCPIP1. 
Twenty-four hours after transfection, the cells were stimulated with IL-17 for four hours. 
Consistent with the earlier observations, reconstitution of MCPIP1 knockout fibroblasts with 
MCPIP1 resulted in a reduced IL-17-dependent IL-6 protein production, compared to the cells 
reconstituted with EV. Taken together, these findings indicate that MCPIP1 is a feedback 
inhibitor of IL-17 signaling. 
  
 99 
 
 
 
 
 
 
 
 100 
Figure 5.1 Contd. 
 
Figure 5.1: MCPIP1 inhibits IL-17 signaling. 
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(A) Induction of endogenous Zc3h12a mRNA expression by IL-17. ST2 cells were treated with 
IL-17 (200 ng/ml) for the indicated times and Zc3h12a mRNA abundance was assessed by 
qPCR in triplicate assays. Data are presented as the fold-induction in Zc3h12a mRNA 
abundance compared to untreated cells. (B) MCPIP1 knockdown enhances the production of 
IL-6 protein. ST2 cells were transfected with siRNA specific for Act1 or MCPIP1 or with a 
scrambled siRNA control, and the amount of IL-6 in culture media was assessed in triplicate at 
three hours after treatment with IL-17 (200 ng/ml). Black bars indicate IL-17-treated samples, 
and white bars indicate untreated samples. (C) MCPIP1 knockdown enhances multiple IL-17 
target gene expression. ST2 cells transfected with the indicated siRNAs and left untreated or 
treated with IL-17 for 3 hours were analyzed for the expression of the indicated genes by qPCR. 
Successful knockdown of Zc3h12a was also confirmed by qPCR. (D) Reconstitution of 
MCPIP1-/- fibroblasts inhibits IL-17 signaling. MCPIP1-/- tail tip fibroblasts were transfected in 
triplicate with EV or murine A20 and either left untreated or treated with IL-17 for 4 hours. IL-6 
protein in supernatants was assessed by ELISA. *P <0.05 by ANOVA with post-hoc Tukey’s 
test compared to cells transfected with control siRNA or EV and treated with IL-17. 
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5.2.2 Mechanism of MCPIP1-mediated IL-17 signaling is distinct from USP25 and A20. 
DUBs such as USP25 and A20 inhibit TLR and IL-17R signaling pathways [85, 92, 158, 159]. 
Since MCPIP1 also functions as a DUB in the TLR pathway [101], we examined whether 
MCPIP1-mediated inhibition of IL-17 signaling is redundant with USP25 and A20. We 
transfected ST2 cells with siRNA targeting MCPIP1 alone or in combination with siRNA 
targeting A20 or Usp25. The cells were either left unstimulated or stimulated with IL-17 for 
three hours. As expected, knockdown of MCPIP1, A20 or USP25 resulted in a significant 
increase in IL-17-dependent IL-6 protein production (measured by ELISA), compared to control 
siRNA. Furthermore, double knockdown of MCPIP1 with either A20 or USP25 resulted in an 
additional increase in IL-17-dependent IL-6 production over individual knockdown of MCPIP1, 
A20 or USP25 (Figure 5.2). Hence, the inhibitory role of MCPIP1 in IL-17R signaling is non-
redundant to other known deubiquitinase inhibitors of this pathway.  
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Figure 5.2: Mechanism of MCPIP1-mediated IL-17 signaling is distinct from USP25 and 
A20. 
MCPIP1 knockdown in combination with USP25 or A20 further enhances IL-6 production. ST2 
cells were transfected with the indicated siRNA and the amount of IL-6 in culture media was 
assessed in triplicate at three hours after treatment with IL-17. *P <0.05 by ANOVA with post-
hoc Tukey’s test compared to cells transfected with control siRNA or EV and treated with IL-
17. 
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5.2.3 Co-expression of MCPIP1 reduces IL-17RA and IL-17RC expression, but does not 
affect Act1 or TRAF6. 
IL-17RA is involved in the activation as well as inhibition of IL-17 signaling [33, 89, 90, 158]. 
Therefore, we evaluated the potential association of IL-17 receptor subunits, IL-17RA and IL-
17RC, with MCPIP1. Plasmids expressing murine IL-17RA or IL-17RC (Myc-tagged at the C-
terminus) were co-transfected with a plasmid expressing murine MCPIP1 in HEK293T cells. 
Surprisingly, expression of MCPIP1 with either of the IL-17R subunits resulted in a striking 
reduction in the expression of IL-17RA and IL-17RC, as detected by western blotting with an 
anti-Myc antibody (Figure 5.3-A). We also confirmed the MCPIP1-mediated reduction in IL-
17RA expression by immunoblotting with an antibody that detects IL-17RA directly (Figure 
5.3-B). 
Next, we asked whether MCPIP1 targeted other factors in the IL-17R signaling pathway. 
Act1 and TRAF6 are both essential for the activation of IL-17R signaling. Therefore, we co-
transfected plasmids expressing Act1 and MCPIP1 in HEK293T cells and analyzed Act1 
expression by western blotting. We did not observe any alteration in Act1 expression in the 
presence of MCPIP1 (Figure 5.3-C). Similar to the full length Act1, MCPIP1 did not affect the 
expression of Act1 mutants that lack ubiquitin ligase activity (dUbox) or IL-17R binding ability 
(dSEFIR) (Figure 5.3-C). MCPIP1 also did not impact TRAF6 expression (Figure 5.3-D). 
Therefore, we conclude that MCPIP1 specifically targets IL-17RA and IL-17RC, but not 
receptor proximal proteins such as Act1 and TRAF6. 
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Figure 5.3: Co-expression of MCPIP1 reduces IL-17RA and IL-17RC expression, but does 
not affect Act1 or TRAF6. 
(A) MCPIP1 targets IL-17RA and IL-17RC. HEK293T cells were transfected with murine IL-
17RA and IL-17RC (Myc-tagged at the C-terminus) together with murine MCPIP1. WCL were 
blotted with anti-Myc to detect IL-17RA and IL-17RC. Blotting with anti-MCPIP1 Abs 
confirmed MCPIP1 expression and tubulin was used as a loading control. (B) Lysates from 
previous experiment were blotted with IL-17RA Abs to determine IL-17RA expression. (C, D) 
MCPIP1 does not degrade Act1 or TRAF6. HEK293T cells were transfected with plasmids 
expressing (Left) murine Act1 full length (Act1 WT), Act1 deletion mutants (Act1 dUbox, Act1 
dSEFIR) or (Right) murine TRAF6 together with construct expressing murine MCPIP1. Act1 
and TRAF6 expression was determined by blotting WCL with anti-Act1 and anti-TRAF6 
antibodies. Expression of MCPIP1 and Tubulin in WCL is indicated (bottom). 
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5.2.4 MCPIP1-mediated decrease in total IL-17RA protein results in reduced receptor 
surface expression. 
IL-17 signal transduction is activated upon IL-17 binding to IL-17RA and IL-17RC at the 
surface of IL-17 target cells. Therefore, we tested whether the decrease in total IL-17RA upon 
co-expression with MCPIP1 translates to a reduced surface expression of the receptor. To assess 
the effect of MCPIP1 on IL-17RA cell surface levels, we transfected HEK293T cells with 
plasmids expressing either IL-17RA alone or in combination with MCPIP1. Twenty-four hours 
later, these cells were stained with antibodies detecting IL-17RA. We observed that the co-
expression of MCPIP1 with IL-17RA resulted in a reduced expression of IL-17RA at the 
surface of HEK293T cells, determined by a shift in the peak representing IL-17RA positive 
cells (Figure 5.4-A). 
To verify that the reduced IL-17RA surface expression was indeed due to reduced 
protein level and not an artifact of co-expressing plasmids, we co-transfected IL-17RA with 
either TRAF6 or A20. Both TRAF6 and A20 play an important role in the regulation of IL-17R 
signaling but have not been reported to directly impact IL-17RA expression. As expected, cells 
expressing IL-17RA alone or in combination with TRAF6 or A20 exhibited a similar IL-17RA 
surface expression pattern (Figure 5.4-B). Altogether, these findings indicate that MCPIP1 
targets IL-17 receptor subunits and results in a reduction of IL-17R expression. 
 
 108 
 
 
Figure 5.4: MCPIP1-mediated decrease in total IL-17RA protein results in reduced 
receptor surface expression. 
(A) MCPIP1 regulates IL-17RA surface expression. HEK293T cells were transfected with 
murine IL-17RA with either EV or murine MCPIP1. Twenty-four hours later the cells were 
harvested, stained with anti-IL-17RA antibodies and counterstained with flourochrome 
conjugated anti-mouse secondary antibody. (B) HEK293T cells were transfected with murine 
IL-17RA with EV, murine TRAF6 or murine A20. Cells were stained as described in Section 
2.2.9. These experiments were conducted by Juan Agustin Cruz. 
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5.2.5  MCPIP1 regulates TLR4 expression. 
MCPIP1 has been previously described as an inhibitor of TLR signaling, activity that requires 
both DUB and RNase functions of MCPIP1 [101, 180, 188]. Based on our observation that 
MCPIP1 inhibits IL-17RA expression, we hypothesized that MCPIP1 has a similar effect on 
TLR4 expression. Therefore, we transfected HEK293T cells with plasmids expressing TLR4 
and MCPIP1. Similar to IL-17RA, presence of MCPIP1 resulted in reduced total TLR4 
expression, measured by western blotting (Figure 5.5). This is to our knowledge the first report 
of a MCPIP1-dependent reduction in inflammatory receptor expression by MCPIP1. Therefore, 
we propose that MCPIP1 inhibits TLR4 and IL-17R signaling by targeting receptor expression, 
in addition to destabilizing the mRNA of inflammatory genes such as Il6 and Il12b. 
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Figure 5.5: MCPIP1 regulates TLR4 expression. 
MCPIP1 targets TLR4. HEK293T cells were transfected with murine TLR4- HA-tagged (1ug or 
2ug) together with murine MCPIP1. TLR4 expression in WCL was detected by western blotting 
with anti-HA Abs. 
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5.2.6 MCPIP1 regulates IL-17RA and IL-17RC by mRNA degradation. 
MCPIP1 is an RNase that degrades Il6 and Il12b mRNA [183]. Therefore, we hypothesized that 
MCPIP1 regulates expression of IL-17RA by degrading its mRNA. To determine the effect of 
MCPIP1 on Il17ra mRNA expression, we transfected an IL-17RA-expressing construct 
together with an increasing amount of MCPIP1 expressing plasmid in HEK293T cells. Twenty-
four hours later, these cells were harvested and Il17ra mRNA levels were determined by qPCR. 
Indeed, we detected that IL-17RA mRNA expression was abrogated in the presence of MCPIP1 
(Figure 5.6-A). Notably, even the smallest dose of MCPIP1 construct used in this assay 
resulted in a significant reduction in Il17ra transcript. We also observed a similar pattern of IL-
17RC mRNA degradation when expressed along with MCPIP1 (Figure 5.6-B). 
Consistent with earlier findings, we observed no effect of MCPIP1 on the expression of 
traf3ip2 (encoding Act1) mRNA (Figure 5.6-C). Therefore, we conclude that MCPIP1 impacts 
Il17ra and Il17rc mRNA expression, suggesting a mechanism of inhibition of IL-17R signaling. 
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Figure 5.6: MCPIP1 regulates IL-17RA and IL-17RC by mRNA degradation. 
(A) MCPIP1 degrades Il17ra mRNA. HEK293T cells were transfected with IL-17RA together 
with increasing concentrations of MCPIP1 expressing plasmid (0-0.75 µg). Il17ra mRNA 
expression by measured by qPCR and normalized to the cells transfected with IL-17RA in the 
absence of MCPIP1. (B, C) MCPIP1 degrades Il17rc mRNA but not Act1 mRNA. HEK293T 
cells were transfected with either IL-17RC (B) or Act1 (C) plasmids together with increasing 
concentrations of MCPIP1 (0-0.75 µg). Il17ra and traf3ip2 mRNA expression by measured by 
qPCR and normalized to the cells transfected with constructs expressing only IL-17RC or Act1 
respectively. These experiments were conducted in collaboration with Juan Agustin Cruz. 
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5.2.7 RNase activity is essential for MCPIP1-mediated IL-17 receptor degradation and 
IL-17 signaling inhibition. 
MCPIP1 RNase function is dependent on the N-terminal nuclease domain as well as the CCCH 
zinc finger. MCPIP1 mutants lacking crucial charged aspartate residues in the RNase domain 
(D225/226A), lacking complete zinc finger domain (ΔZF) or a point mutant (C306R), lack the 
ability to degrade MCPIP1 target mRNA transcripts such as Il6. (Figure 5.7-A). Because 
MCPIP1 functional domains are conserved across several species, we used constructs 
expressing human MCPIP1 (provided by our collaborator Dr. Pappachan E. Kolattukudy, 
University of Central Florida). To confirm the importance of MCPIP1 RNase activity in 
targeting IL-17RA, we transfected constructs expressing murine IL-17RA along with plasmids 
expressing WT MCPIP1 or one of the above-mentioned RNase mutants. Consistent with 
reduced IL-17RA protein levels when co-expressed with murine MCPIP1, human MCPIP1 also 
resulted in a similar decrease in IL-17RA expression, as determined by western blot analysis of 
the whole cell extract. However, we did not observe any decrease in IL-17RA protein levels in 
the presence of MCPIP1 mutants lacking RNase activity (Figure 5.7-B), establishing the 
importance of MCPIP1 RNase function in regulating IL-17RA mRNA and subsequent protein 
expression. 
Next, we examined whether MCPIP1 RNase activity is required for in the inhibition IL-
17R signaling. Murine MCPIP1 knockout fibroblasts were reconstituted with plasmids 
expressing either wild type MCPIP1 or MCPIP1 mutant C306R. Twenty-four hours later, these 
cells were stimulated with IL-17 for four hours and supernatants were evaluated for IL-6 by 
ELISA. As expected, MCPIP1 expression resulted in reduced IL-17-dependent IL-6 production 
as compared to EV. However, MCPIP1 C306R did not suppress IL-6 production. We also 
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observed a comparable lack of inhibition of IL-17 dependent Il6 mRNA expression upon 
reconstitution with MCPIP1 C306R (Figure 5.7-C). Collectively, these data indicate that 
MCPIP1 facilitates Il17ra/Il17rc mRNA degradation and restricts IL-17 signaling through its 
RNase and zinc finger domains. 
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Figure 5.7: RNase activity is essential for MCPIP1-mediated IL-17 receptor degradation 
and IL-17 signaling inhibition. 
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(A) Schematic diagram of MCPIP1 domains. ZnF, Zinc Finger; locations of RNase, Proline rich 
region and MCPIP1 phosphorylation sites are indicated. (B) MCIP1 mutants of MCPIP1 impair 
its ability to target IL-17RA. HEK293T cells were transfected with murine IL-17RA (tagged at 
the C-terminus with Myc) together with constructs expressing human MCPIP1 or indicated 
mutants. IL-17RA expression was detected by western blotting with anti-Myc Abs whereas 
MCPIP1 and its mutants were detected with anti-MCPIP1 antibody. (C) MPCIP1 RNase 
function is important to inhibit IL-17 signaling. MCPIP1-/- tail tip fibroblasts were reconstituted 
with plasmids expressing EV, human MCPIP1 (WT) or human MCPIP1 (C306R) mutant. 
Twenty-four hours later, cells were either left untreated or stimulated with IL-17 for 4 hours and 
the amount of IL-6 in culture media was assessed by ELISA. n.s. Not significant, *P <0.05 by 
ANOVA with post-hoc Tukey’s test compared to cells transfected with EV and treated with IL-
17. 
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5.2.8 MCPIP1 targets IL-17RA through its N-terminal coding region. 
MCPIP1 destabilizes its target mRNAs, such as Il6 and c-Rel, by targeting stem-loop structures 
in their 3’ untranslated region (UTR) [183, 190]. Although MCPIP1 also degrades Il17ra and 
Il17rc transcripts, the constructs expressing these IL-17R subunits in our system do not include 
the respective 3’ UTR sequences. Therefore, we hypothesized that sequences within the 
receptor coding regions might be targets for mRNA degradation by MCPIP1. 
To identify the Il17ra sequence targeted by MCPIP1, we transfected HEK293T cells 
with constructs expressing MCPIP1, along with either full length (FL) IL-17RA, IL-
17RA∆SEFIR or IL-17RA.V553H and assessed the total IL-17RA protein by western blotting 
(Figure 3.10A). Expression of IL-17RA.FL, IL-17RA∆SEFIR and IL-17RA.V553H was 
efficiently reduced upon co-expression with MCPIP1 (Figure 5.8-B). Although we could detect 
some expression of IL-17RA∆SEFIR even in the presence of MCPIP1, we believe that is due to 
higher baseline expression of the IL-17RA.∆SEFIR mutant. Next, we transfected plasmids 
expressing IL-17RA mutants lacking specific C-terminal residues. For example, IL-17RAΔ665 
lacks amino acid residues downstream of position 665. The expression of truncation constructs 
and IL-17RA degradation in the presence of MCPIP1 were determined by western blotting. All 
the mutants tested were degraded by MCPIP1 (Figure 5.8-A,C). Cumulatively, these data 
suggest that Il17ra sequence targeted by MCPIP1 is 5’ of nucleotides at position 1276-1278 
(encoding IL-17RA amino acid residue 426). 
Because amino acid at position 426 is close to IL-17RA transmembrane domain, we 
questioned whether deleting the transmembrane domain would rescue Il17ra mRNA from 
MCPIP1-mediated degradation. Therefore, we transfected the MCPIP1-expressing plasmid in 
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combination with either IL-17RA.FL or IL-17RA constructs expressing mRNA from 
nucleotides at position 1 to 775 (IL-17RAΔ258). As IL-17RAΔ258 lacks the transmembrane 
domain, we directly determined Il17ra mRNA expression by qPCR. IL-17RA.FL and IL-
17RAΔ258 mRNA were degraded to a similar level when expressed with MCPIP1 (Figure 5.8-
A,D). Therefore, we conclude that MCPIP1 targets Il17ra mRNA sequence between nucleotides 
1 and 775. Further truncations will be required to determine the smallest possible Il17ra mRNA 
sequence targeted by MCPIP1. 
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Figure 5.8 Contd. 
 
 
Figure 5.8: MCPIP1 targets the N-terminal region of IL-17RA. 
(A) Schematic diagram of IL-17RA domains and C-terminal truncation mutants. ECD, 
extracellular domain; TM, Transmembrane; locations of SEFIR/SEFEX and CBAD domains 
are indicated. Also, the numbers depict the last expressed amino acid residue of that particular 
truncation construct. (B) MCPIP1 degrades IL-17RA in a SEFIR/SEFEX-independent manner. 
HEK293T cells were transfected with murine IL-17RA and indicated mutants (tagged at the C-
terminus with HA) with or without murine MCPIP1. Anti-HA Abs was used to detect IL-17RA 
expression in WCL. Expression of MCPIP1 in WCL is indicated (bottom). (C) MCPIP1 does 
not target sequences that encode for C-terminal IL-17RA region. HEK293T cells were 
transfected with indicated murine IL-17RA mutants (C-terminal Myc-tagged) along with 
murine MCPIP1 and blotted for IL-17RA with anti-Myc Abs. (D) MCPIP1 degrades IL-17RA 
though its N-terminal coding sequence.  HEK293T cells were transfected with murine IL-17RA 
(full length) or IL-17RAΔ258 along wit increasing concentration of murine MCPIP1 (0 to 
0.5ug). Il17ra mRNA expression was determined by qPCR and normalized to the cells 
transfected with IL-17RA in the absence of MCPIP1. 
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5.2.9 IL-17RA deletion in MCPIP1 knockout mice does not result in enhanced survival.        
MCPIP1 knockout mice (MCPIP1-/-) have been generated and described previously [101, 183]. 
Deletion of MCPIP1 in mice results in growth retardation after weaning, severe splenomegaly 
and lymphadenopathy. Moreover, MCPIP1-/- mice have elevated serum levels of 
proinflammatory proteins such as TNFα and MCP-1 [101]. As a result, these mice die 
prematurely, with a median survival of approximately 7-8 weeks. Inflammation in MCPIP1-/- 
mice is due in part to a lack of regulatory function of MCPIP1 in T cells as well as LPS and IL-
1β signaling [189, 190]. 
 Although MCPIP1-/- mice have an elevated number of TH17 cells, it is not known 
whether enhanced IL-17 production or signaling drives baseline inflammation in these mice. As 
we observed that MCPIP1 inhibits IL-17 signaling, we hypothesized that IL-17 is involved in 
driving inflammation in MCPIP1-/- mice. Therefore,  we crossed MCPIP1-/- mice to IL-17RA-/- 
mice and obtained MCPIP1-IL-17RA double knockout mice (MCPIP1-/- IL-17RA-/-). 
Surprisingly, similar to MCPIP1-/- mice, MCPIP1-/- IL-17RA-/- mice also display growth 
retardation and spontaneous inflammation in spleen and lymph nodes (data not shown).  We 
also determined the survival kinetics in both groups of mice and found no difference (Figure 
5.9). Thus, we conclude that IL-17 signaling is not required for the persistent inflammation in 
MCPIP1-/- mice. In fact, a recent report suggests that inflammation in MCPIP1-/- mice is driven 
by endogenous microbiota of mucosal surfaces, particularly the intestinal microflora, since 
antibiotic treatment in drinking water alleviated the inflammation in MCPIP1-/- mice. 
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Figure 5.9: IL-17RA deletion does not enhance survival of MCPIP1 knockout mice. 
Crossbreeding of MCPIP1-/- and IL-17RA-/- mice. To generate MCPIP1-/- IL-17RA-/- mice, we 
bred MCPIP1+/- to IL-17RA-/- mice. After several rounds of breeding, we obtained MCPIP1-/- 
IL-17RA-/- mice and compared the survival kinetics of MCPIP1-/- and MCPIP1-/- IL-17RA-/-. 
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5.2.10  MCPIP1 deficiency in mice leads to enhanced protection from disseminated 
Candida albicans infection that is dependent on IL-17RA. 
IL-17 is vital in controlling infections from fungi such as Candida albicans. Based on our 
observation that MCPIP1 inhibits IL-17 signaling and that Zc3h12a expression is increased 
during oral C. albicans infection, we hypothesized that MCPIP1 knockout have persistent IL-17 
signaling in vivo and as a result, would be protected from C. albicans infection. However, 
MCPIP1-/- mice die prematurely and have multi-organ inflammation, precluding their use for 
experimentation. Therefore, we tested MCPIP1 heterozygous mice (MCPIP1+/-) and conducted 
inflammatory gene expression analysis in multiple organs including kidneys, lungs and gut. 
Although the levels of inflammatory cytokine mRNA transcripts in most organs in MCPIP1+/- 
were comparable to WT mice, we detected elevated mRNA expression of inflammatory 
cytokines such as IL-6, IL-17 and IFN-γ in the gut of MCPIP1+/- mice (data not shown). 
However, these conclusions are preliminary, as these experiments were conducted only once 
with one animal per group, and so require further verification to draw any firm conclusions 
about inflammation in MCPIP1+/- mice. Nevertheless, compared to MCPIP1-/- animals, 
MCPIP1+/- mice do not have overt baseline inflammation and are suitable for use in 
experimental models. 
We infected MCPIP1+/- mice with 2x105 C. albicans via their tail veins and compared 
them to age- and sex-matched MCPIP1 wild-type (WT or MCPIP1+/+) mice. In this infection 
model, C. albicans disseminates to multiple organs, particularly kidneys [194, 195]. Two days 
post-infection, these mice were euthanized and fungal load in the kidneys was assessed. As 
expected, based on previous publications, C. albicans infection in WT mice resulted in a very 
high fungal burden in kidneys (approximately 106 cfu per gram of tissue). Although MCPIP1+/- 
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mice do not completely clear the infection, these mice displayed a significantly lower fungal 
load, compared to WT mice (Figure 5.10-A), supporting the idea that MCPIP1+/- mice have 
enhanced inflammatory signaling. 
Previous studies have shown that IL-17RA-/- mice are more susceptible to disseminated 
C. albicans infection, indicating an important role of IL-17 in host defense against C. albicans 
[196]. Therefore, we aimed to verify that the reduced fungal load in MCPIP1+/- mice is due to 
enhanced IL-17 signaling. To ascertain the direct role of IL-17R signaling, we used MCPIP1+/- 
mice that were crossed to IL-17RA-/- mice. The resultant mice were heterozygous for MCPIP1 
gene and were completely knocked out for IL-17RA expression (MCPIP1+/-IL-17RA-/-). These 
mice were also infected with 2x105 Candida albicans via the tail vein and compared to WT, 
MCPIP1+/- and IL-17RA-/-mice. Consistent with earlier reports, IL-17RA-/- mice had higher 
fungal burdens than WT mice. Furthermore, we confirmed our earlier finding that MCPIP1+/- 
mice had reduced fungal load in kidneys. However, MCPIP1+/- IL-17RA-/- mice were unable to 
control the infection and had a fungal load similar to WT mice (Figure 5.10-B). These data 
clearly demonstrate that the control of fungal infection in MCPIP1+/- mice is due to the role of 
MCPIP1 in regulating IL-17R signaling. 
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Figure 5.10: MCPIP1 deficiency in mice leads to enhanced protection from disseminated 
Candida albicans infection that is dependent on IL-17RA. 
(A) Regulation of disseminated candidiasis infection by MCPIP1 heterozygous mice. 
MCPIP1+/+ (WT) and MCPIP1+/- mice (n=5 per group) infection with C. albicans and kidney 
harvest have been explained in Section 2.2.6. C. albicans colony forming units (cfu) in kidneys 
were determined by counting C. albicans colonies on YPD agar plates. (B) Control of C. 
albicans infection in MCPIP1 heterozygous mice is dependent on IL-17RA. MCPIP1+/+ (WT) 
and MCPIP1+/-, MCPIP1+/- IL-17RA-/- and IL-17RA-/- mice (n=5 per group) were infected and 
assessed for kidney C. albicans cfu as described earlier. Data presented as Arithmetic mean ± 
SEM. These experiments were conducted in collaboration with Drs. Heather Conti, Natasha 
Whibley and Partha Biswas, University of Pittsburgh. 
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5.2.11  IL-17 induced pulmonary inflammation is enhanced in MCPIP1 heterozygous 
mice. 
Administration of IL-17 through the airways induced the production of inflammatory cytokines 
and chemokines production that leads to the recruitment of neutrophils to the lungs [53, 92]. 
Therefore, to verify that MCPIP1 regulates IL-17 signaling in vivo, we treated mice with 
recombinant IL-17 through the intranasal route. WT and MCPIP1+/- mice were either left 
unchallenged or treated with IL-17 (300 ng/mouse). Twenty-four hours later, we analyzed 
immune cell infiltrate in BALF and well as inflammatory gene expression in the lungs.  
As expected, we only detected a very low percentage of neutrophils (Gr-1+, F4/80-) in 
the BALF of unchallenged mice, which increased significantly upon IL-17 challenge. 
Furthermore, there was a significant increase in the percentage of neutrophils in MCPIP1+/- mice 
as compared to WT mice (Figure 5.11-A). Consistent with the enhanced neutrophil infiltration, 
we detected elevated expression of IL-17 target genes such as cxcl1 and cxcl5 in the lungs (but 
not Il6), measured by qPCR (Figure 5.11-B). Although the changes in gene expression were not 
statistically significant between WT and MCPIP1+/- mice, these data are consistent with our 
earlier observations and warrants further investigation with additional mice to confirm the 
results and statistical significance. To summarize, these preliminary data further support an 
inhibitory role for MCPIP1 in IL-17R signaling in vivo. 
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Figure 5.11 Contd. 
 
 
 
Figure 5.11: IL-17 induced pulmonary inflammation is enhanced in MCPIP1 
heterozygous mice. 
(A) IL-17-induced pulmonary inflammation is enhanced in MCPIP1+/-. MCPIP1+/+ (WT) and 
MCPIP1+/- mice (n = 2 per group) were given intranasal injection of IL-17 (300 ng in 50 μl 
PBS) or left unchallenged. Infiltration of neutrophils (Gr-1+F4/80-) into the BALF was assessed 
24 hours after injection (described in detail in Section 2.2.7). (B) CXCL1, CXCL5 and IL-6 
mRNA expression in the lungs isolated from mice treated in (A) was determined by qPCR. 
These experiments were conducted in collaboration with Dr. Kong Chen and Dr. Jay Kolls, 
University of Pittsburgh. 
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5.2.12 MCPIP1 deficiency exacerbates EAE severity. 
IL-17 signaling plays a critical role in the development of EAE, an autoimmune disease mouse 
model of human multiple sclerosis [66, 90, 92]. Enhanced IL-17 signaling has been associated 
with increased severity of disease in mice [90, 92]. To investigate the role of MCPIP1 in IL-17 
signaling during autoimmune disease, we induced EAE in WT and MCPIP1+/- mice and 
monitored the mice every day for signs of clinical disease using a scoring scheme described in 
section 2.2.8.  
We observed that the onset of disease as well as initial clinical scores were similar in 
WT and MCPIP1+/- mice. However, as the disease progressed, the severity of EAE pathology 
was significantly greater in MCPIP1+/- mice (Figure 5.12), indicating that MCPIP1-mediated 
regulation of IL-17 signaling is relevant in the control autoimmune disease progression. To 
confirm these findings and to eliminate the possible contribution of additional inflammatory 
pathways in the development of EAE, we plan to repeat these experiments with more mice as 
well as with MCPIP1+/- IL-17RA-/- mice. 
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Figure 5.12: MCPIP1 deficiency exacerbates EAE severity. 
EAE severity is enhanced in the absence of MCPIP1. (a) MCPIP1+/+ (WT) and MCPIP1+/- mice 
(n = 4 per group) were challenged with MOG-CFA and pertussis toxin to induce EAE. The 
mice were scored everyday for signs of clinical disease on a scale of 1 to 6. (described in 
Section 2.2.8). This experiment was conducted in collaboration with Dr. Mandy McGeachy, 
University of Pittsburgh. 
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5.3 DISCUSSION 
The proinflammatory activity of IL-17 is vital in regulating extracellular bacterial and fungal 
infections both in mice and humans. IL-17 exerts these functions by inducing the expression of 
several cytokines, chemokines and anti-microbial peptides. Similar to other inflammatory 
cytokines such as TNFα and IL-1β, IL-17 induces these genes by activating a complex cascade 
of signaling molecules. Conversely, inhibition of IL-17 signaling is important to avoid collateral 
damage from IL-17-induced inflammation. Therefore, multiple inhibitory molecules work 
together to ‘put brakes’ on IL-17 signaling. The work described earlier in this thesis includes 
two inhibitors of IL-17 signal transduction, A20 and AnapC5. 
In an effort to identify additional novel feedback inhbitors, we mined previously-
generated microarray data analyzing IL-17-dependent gene expression upon oral C. albicans 
infection [28]. Through this screen we identified Zc3h12a, which was initially discovered as a 
gene induced by MCP-1. Subsequently, other inflammatory stimuli such as IL-1β and LPS have 
also been shown to induce Zc3h12a expression.  Zc3h12a encodes MCPIP1, which belongs to a 
family of CCCH-type zinc finger proteins that exhibit RNase activity. Indeed, MCPIP1 
functions as an RNase and degrades Il6 and Il12 mRNA [183]. Furthermore, MCPIP1 also has 
DUB acitivity and deubiquitinates TRAFs [101]. Presumably as a cumulative result of these 
enzymatic actions, MCPIP1 inhibits TLR4, IL-1R and TNFR signaling pathways. IL-17 shares 
many activation mechanisms and target genes with IL-1β and TLRs. Therefore, we examined 
whether MCPIP1 also inhibits the IL-17 pathway. Accordingly, here we extend MCPIP1 
function as an inhibitor of IL-17 signal transduction. 
Using RNA silencing and MCPIP1-/- cells, we show that MCPIP1 inhibits IL-17-induced 
target gene expression (Figure 5.1). In TLR and IL-1R pathways, the inhibitory function of 
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MCPIP1 is attributed mainly to the degradation of target gene mRNA and deubiquitination of 
adaptor proteins. In IL-17 signaling, IL-17RA and IL-17RC have been previously linked with 
direct recruitment of both activators and inhibitors of IL-17 signaling (Chapter 3-4). Therefore, 
we tested whether IL-17RA and IL-17RC physically associate with MCPIP1. Surprisingly, co-
expression of MCPIP1 with IL-17RA or IL-17RC led to a substantial reduction in the 
expression of both receptor subunits (Figure 5.2). Upon further analysis, we found that 
MCPIP1 mediates Il17ra mRNA degradation, which ultimately results in reduced surface 
expression of IL-17R.  Degradation of Il17ra and Il17rc appears to be specific, as MCPIP1 had 
no effect on Act1 and TRAF6 expression (Figure 5.3-5.6).  
MCPIP1-mediated degradation of Il17ra transcript occurs through the RNase and zinc 
finger domains of MCPIP1, as mutants lacking either of these domains lack the ability to 
degrade the receptor transcripts (Figure 5.7).  MCPIP1 degrades Il6 mRNA by targeting a stem-
loop structure in its 3’UTR [183]. Interestingly, the Il17ra sequence targeted by MCPIP1 in the 
in vitro experiments expresses the coding sequence but not the 3’UTR. Therefore, to assess 
whether the IL-17RA mRNA sequence also contains a putative stem-loop structure that is 
recognized by MCPIP1, we tested MCPIP1-mediated degradation of several IL-17RA 
constructs expressing truncated and mutant forms of IL-17RA. This analysis revealed that 
MCPIP1 targets a sequence in Il17ra mRNA between nucleotides 1-775 (Figure 5.8). 
Additional experiments are required to identify the precise sequence and structure of IL-17RA 
sequence recognized by MCPIP1; nonetheless, degradation of IL-17RA coding sequence is an 
exciting finding for multiple reasons. First, MCPIP1 has never been reported to target the 
coding sequence of its target genes. Secondly, degradation of Il17ra and Il17rc mRNA is the 
first report of MCPIP1 degrading its inducing receptor. Based on our findings, we questioned 
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whether MCPIP1-mediated degradation of IL-17R is a broad mechanism of inflammatory 
receptor regulation. Indeed, co-expression of MCPIP1 and TLR4 resulted in reduced expression 
of TLR4 (Figure 5.8). Therefore, we have not only uncovered MCPIP1 as an inhibitor of IL-17 
signaling but also identified a novel mechanism by which MCPIP1 potentially regulates other 
inflammatory signaling pathways (Figure 5.13). 
MCPIP1, like A20 and TTP, is a key player in  regulating tonic inflammatory signaling. 
As a result, MCPIP1-/- mice suffer from systemic multi-organ inflammation, growth retardation 
and premature death [101, 183]. Therefore, we crossed MCPIP1-/- mice to IL-17RA-/- mice to 
determine whether IL-17-induced inflammation is the root cause of abnormal inflammation in 
MCPIP1-/- mice. However, MCPIP1-/- IL-17RA-/- mice were not rescued from systemic 
inflammation and early death (Figure 5.9), suggesting that IL-17 could not be involved in 
driving inflammation in MCPIP1-/- mice. 
To verify further the physiological relevance of MCPIP1-mediated inhibition of IL-17 
signaling, we examined MCPIP1+/- mice in a variety of mouse models. As expected, deficiency 
of MCPIP1 results in enhanced protection from disseminated C. albicans infection, which is 
dependent on IL-17RA. Furthermore, as compared to WT mice, MCPIP1+/- mice have more 
severe disease symptoms when subjected to EAE. Finally, direct treatment with recombinant 
IL-17 through an intranasal route results in enhanced neutrophil recruitment and inflammatory 
chemokine expression in MCPIP1+/- mice (Figure 5.10-5.12). Cumulatively, these data suggest 
that MCPIP1 is involved in the regulation of IL-17 signaling  in vivo. 
In order to address the complete scope of MCPIP1-mediated inhibition of IL-17 
signaling, more in depth exploration is clearly required. MCPIP1 functions as an RNase and 
degrades multiple other cytokine mRNAs in addition to that encoding IL-17R. However, it is 
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still unknown what determines the specificity of MCPIP1 target sequences. In some cases, 
enzymes recruit adaptor proteins to aid their activity, but it is not known whether MCPIP1 uses 
any adaptors. We discovered that MCPIP1 degrades inflammatory receptor transcripts such as 
those encoding IL-17R and TLR4, but it is not known whether MCPIP1-mediated degradation 
of receptor mRNA is a widespread function or is limited to MCPIP1-inducing receptors (IL-
17R, TLR4). Also, MCPIP1 DUB activity is important in the regulation of TLR4 signaling, but 
its role in IL-17 signaling still needs to assessed. 
MCPIP family members are closely related but not identical. Understanding the function 
of MCPIP1, the prototypical member function of the MCPIP family, could provide interesting 
insight into the function of other family members. For example, owing to their similarlities in 
sequence, MCPIP family proteins could either act as dominant negative factors or work as 
compensatory proteins in the absence of MCPIP1. Finally, as MCPIP1 inhibits multiple 
inflammatory signaling pathways, any interesting insight into the mechanism of MCPIP1-
mediated regulation of IL-17 signaling could potentially be applicable to LPS, IL-1β and TNFα 
signaling. 
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Figure 5.13: Schematic diagram of MCPIP1-mediated inhibition of IL-17 signaling. 
MCPIP1 serves as a feedback inhibitor of IL-17 signaling by inhibiting IL-17 target gene 
expression. MCPIP1 also directly degrades IL-17RA and IL-17RC mRNA, suggesting a model 
where MCPIP1 inhibits IL-17 signal transduction through multiple mechanisms. 
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6.0  CONCLUSIONS AND FUTURE DIRECTIONS  
 137 
6.1 SUMMARY 
The IL-17 family is the newest addition to the inflammatory cytokine families, which include 
TNF and IL-1. IL-17 induces proinflammatory gene expression by activating a signal 
transduction pathway involving Act1 and TRAF6, ultimately resulting in the activation of NF-
κB, C/EBPs and MAPKs. Additionally, several proteins are involved in the inhibition of IL-17R 
signaling. The data presented in this thesis have advanced our understanding of the mechanisms 
involved in the inhibition of IL-17 signal transduction. Here we identified three proteins that 
negatively regulate IL-17 signaling by different mechanisms. 
Our studies demonstrated that A20 is a feedback inhibitor of IL-17R signaling (Chapter 
3). IL-17 induced Tnfaip3 gene expression through NF-κB, which resulted in elevated A20 
protein levels. A20 directly associated with TRAF6 in an IL-17-dependent manner and 
deubiquitinated TRAF6. These events resulted in reduced NF-κB and MAPK activity and 
subsequent reduction on IL-17-induced gene expression. A20 bound directly to IL-17RA; 
however, rather than interacting with the SEFIR domain, which is required for IL-17-dependent 
NF-κB activation, A20 bound to the IL-17RA distal domain (CBAD), which inhibits IL-17 
signaling. Together, these data describe a previously unrecognized mechanism of restraining IL-
17 signaling, revealing a dimension of A20 activity that may help to explain its widespread 
effect on autoimmunity in humans. 
Furthermore, we analyzed the role of TAX1BP1 and Itch in facilitating A20-mediated 
inhibition of IL-17 signaling. Both TAX1BP1 and Itch are scaffolding proteins that mediate 
A20 inhibition in the TNFα and IL-1 signaling pathways. However, we did not detect any 
effects of TAX1BP1 or Itch knockdown on IL-17-mediated gene expression, suggesting either 
 138 
that A20 functions alone in IL-17 signaling regulation or that novel signaling intermediates 
assist A20. Therefore, we tested the function of APC complex protein, AnapC7, identified as an 
IL-17RC-associating protein through a yeast-two hybrid screen. Although AnapC7 knockdown 
did not impact IL-17-induced gene expression, we found that a related APC family protein, 
AnapC5, inhibited IL-17R signaling. Strikingly, both AnapC7 and AnapC5 associated with IL-
17RA through the CBAD domain of the receptor. A20 also binds to the IL-17RA CBAD; 
therefore we tested direct association of A20 and AnapC5. Indeed, we observed that AnapC5 
also associated with A20, suggesting a model in which AnapC5, rather than TAX1BP1 or Itch, 
is a novel adaptor and negative regulator of IL-17 signaling pathways and possibly assists A20 
in its role as an inhibitor of IL-17R signaling (Chapter 4).  
The studies described in this thesis also identify MCPIP1 as a novel inhibitor of IL-17 
signaling pathway (Chapter 5). Zc3h12a, the gene-encoding MCPIP1, is also an IL-17 target 
gene. MCPIP1 functions as an RNase in this pathway and targets IL-17 receptor expression by 
degrading Il17ra and Il17rc mRNA. The significance of MCPIP1-mediated inhibition of IL-17 
signaling was demonstrated by enhanced IL-17-induced pulmonary inflammation and severe 
EAE disease severity in MCPIP1+/- mice. Furthermore, amplified inflammation in MCPIP1+/- 
mice resulted in a superior protection from disseminated C. albicans infection in an IL-17-
dependent manner. Finally, we discovered that regulation of receptor expression by MCPIP1 is 
not limited to IL-17R proteins. MCPIP1 also regulates TLR4, indicating a common mechanism 
of inflammatory signaling regulation by MCPIP1. 
Although the inhibitors of IL-17R signaling described in this study function by different 
means, these proteins lead to a common endpoint of restricting IL-17-induced inflammation and 
limiting any resulting collateral damage. In light of these findings, we update the current 
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paradigm of IL-17 signaling to include these feedback inhibitors of IL-17 signaling (Figure 
6.1). 
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Figure 6.1: Schematic model of IL-17 signal transduction. 
Activation of IL-17 signaling involves a complex array of proteins that regulate IL-17 target 
gene expression. Likewise, several inhibitors are involved in facilitating the inhibition of IL-17 
signaling. This diagram is a representation of our current understanding of IL-17 signaling 
including the three inhibitory proteins described in this thesis. 
  
 141 
6.2 OUTSTANDING QUESTIONS AND FUTURE DIRECTIONS 
The studies presented here have focused on the inhibitory pathways involved in the regulation 
of IL-17 signal transduction. A20 is well-recognized inhibitor of inflammatory pathways such 
as TNFα and IL-1β, and now we extend its role to IL-17 signaling. However, further research is 
required to determine fully the contribution of A20-mediated inhibition of IL-17 pathway in 
vivo, this question could potentially be addressed by using A20+/- or A20-/- mice in IL-17-
dependent disease models. Disseminated candidiasis (fungal infection model) or EAE and 
intranasal IL-17 challenge (models of autoimmunity) are examples of some settings where IL-
17 plays a critical role in host protection or inducing autoimmune inflammation. Furthermore, 
like MCPIP1-/- mice, A20-/- mice also have systemic inflammation and die prematurely [124]. 
Earlier studies ascribed inflammation in A20-/- mice to enhanced TLR signaling initiated by gut 
resident microflora [122]. Whether IL-17 plays any role in driving inflammation in A20-/- mice 
can be addressed by crossbreeding A20-/- to either IL-17A-/- or IL-17RA-/- mice. 
Another interesting observation in this study was the direct association of A20 and IL-
17RA. This is the first report of A20 directly associating with its inducing receptor, suggesting a 
possible mechanism by which A20 quickly restricts IL-17 signaling. Since A20 also functions 
as a feedback inhibitor for TNFR, TLR and IL-1R, it would be interesting to test whether these 
signaling pathways also employ receptor-mediated recruitment of A20. Unlike TNFR and IL-
1R pathways, the adaptor proteins TAX1BP1 and Itch do not seem to be relevant in A20-
mediated regulation of IL-17 signaling. Instead, we discovered a novel role of AnapC5 as it 
directly associates with A20 and may aid A20 function in the IL-17 pathway.  In addition to 
further exploring the importance of AnapC5 and related proteins in the recruitment of proteins 
 142 
to IL-17 receptor proximal complex, it would be intriguing to test whether AnapC5 (or related 
proteins) is also involved in other pro-inflammatory signaling pathways. 
MCPIP1 is another feedback inhibitor of IL-17 signaling identified in this study. 
MCPIP1 regulates IL-17 signaling in vitro and in vivo. However, deletion of IL-17RA in 
MCPIP1-/- mice did not alleviate systemic inflammation, suggesting that the baseline 
inflammation in MCPIP1-/- mice is independent of its role in IL-17 signaling. In fact, a recent 
study elegantly demonstrated that MCPIP1 regulates immune homeostasis, owing to its role in 
CD4+ T cells [190]. Another report suggested that the MCPIP1-/- mice treated with antibiotics 
have a significant reduction in inflammatory cytokine expression and display prolonged 
survival [189]. These observations demonstrate that intestinal microflora are at least partially 
responsible for inducing inflammatory phenotype in MCPIP1-/- mice, indicating the significance 
of MCPIP1 in inhibiting TLR and IL-1R signaling. To directly assess the relevance of MCPIP1 
in controlling TLR/IL-1R pathways, we have bred MCPIP1-/- mice to MyD88-/- mice. We 
recently obtained a single MCPIP1-/- MyD88-/- mouse and observed a significant increase in 
survival (data not shown). However, loss of MyD88 and subsequent lack of TLR/IL-1R 
signaling did not result in complete abrogation of inflammation in MCPIP1-/- mice, suggesting 
that the inflammation in MCPIP1-/- mice is probably driven by multiple stimuli. Therefore, it 
would be interesting to further mine the scope of MCPIP1-mediated regulation of inflammatory 
pathways. A few stimulating questions include: Do IL-17 or TNFα drive inflammation in 
MCPIP1-/- MyD88-/- mice? Is MCPIP1-mediated inhibition of TLR and IL-17R signaling cell 
type specific? What are the relative contributions of immune and non-immune compartments? 
Does MCPIP1 also regulate signaling in other immune cells such as dendritic cells (DCs) or 
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macrophages? Tools such as MCPIP1-/- MyD88-/- and MCPIP1-/- IL-17RA-/- mice could prove to 
be useful in answering these questions. 
Besides providing valuable insight into the mechanisms of IL-17 signaling inhibition, 
this study raises some interesting questions about the regulation of IL-17 signaling and 
inflammatory pathways in general. It is intriguing that several proteins are involved in inhibiting 
IL-17 signal transduction. Additionally, proteins such as A20 and MCPIP1 regulate multiple 
pathways including IL-17, TNFα, LPS and IL-1 signaling. There are a few possible 
explanations of this overlap in inhibitor function. First, the mechanisms employed in the 
regulation of IL-17 signaling are not identical to TNFα, LPS or IL-1 pathways. For example, 
A20 inhibits TNFα signaling by deubiquitinating RIP1, whereas in the IL-17, LPS and IL-1 
pathways, TRAF6 is the target protein [197]. Secondly, in the setting of autoimmune conditions 
such as RA, proinflammatory cytokines such as IL-17, TNFα and IL-1 are upregulated [42]. 
Under such circumstances, these cytokines could act in synergy to further induce inflammatory 
cytokines and chemokines. Therefore, the presence of multiple inhibitors that could potentially 
regulate most of these pathways is possibly an effective strategy of counterbalancing 
inflammatory cytokine pathways.  
Finally, it is possible that the kinetics of inhibition vary for different feedback inhibitors, 
allowing the inhibitors to act at different stages after the activation of the signaling pathway. For 
example, A20 and MCPIP1 expression are both induced by IL-17. However, the expression 
kinetics for these proteins are dissimilar. While A20 mRNA expression is induced very early 
and goes down rapidly, MCPIP1 mRNA expression is more gradual and remains elevated for a 
longer period of time. mRNA expression kinetics in addition to the stability of the encoded 
proteins, could potentially determine the timing and efficacy of inhibition. An approach to 
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perform in-depth analysis of such kinetics is to build bioinformatics models of the signaling 
pathways. This kind of modelling approach has been used in the past to determine the kinetics 
of NF-κB activation at steady state as well as in response to inflammatory stimuli such as TNFα 
(reviewed in [198]). We are collaborating with Dr. James Faeder (University of Pittsburgh) to 
develop a computational model of IL-17R signal transduction and A20-mediated inhibition of 
IL-17 signaling. To integrate the biological data and a representative mathematical model, we 
will use the existing data as an input for the construction and calibration of the model. These 
inputs include the kinetics of feedback inhibitor expression, target gene expression and the 
activation status of different proteins involved in the pathway. Furthermore, this model could be 
expanded to include other inhibitors such as MCPIP1 or could be overlayed with models of 
TNFα, LPS and IL-1 signaling to determine the basis of cross talk between the inflammaotry 
signaling pathways. 
A goal of exploring signaling pathways is to identify drug targets that help improve the 
effectiveness of patient care. A standard treatment for many autoimmune conditions is 
inflammatory cytokine neutralization using biologics such as anti-cytokine antibodies. 
However, neutralizing antibodies also decrease the ability to fight infections, and as a 
consequence, patients on biologic therapies are more susceptible to bacterial and fungal 
infections. Also, not all patients respond equally to the neutralizing antibody treatments and are 
treated with different biologics until the effective therapy is identified. Therefore, defining 
molecular signaling intermediates, especially enzymes such as A20 and MCPIP1, has the 
potential to reveal strategies for developing small-molecule therapeutics that target IL-17 
signaling as well as TNFα and IL-1β. Drugs that enhance endogenous inhibitor function could 
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help restrain the effects of IL-17 and other inflammatory cytokines on autoimmune 
inflammation without losing the effector function in host defense. 
However, it is challenging to use chemical drugs to induce gain of function in proteins. 
We postulate that a way for this therapeutic strategy to be effective would be to regulate the 
expression of inhibitory molecules. There is precedent in literature for a similar strategy that has 
proven to be effective in downregulating inflammation. Specifically, an F box protein, Fbx12, 
regulates K48-linked ubiquitination and proteasomal degradation of TRAFs 1-6. F box proteins 
belong to the SCF superfamily of E3 ubiquitin ligases and are important for substrate 
recognition by these ubiquitin ligase complexes. Another E3 ubiquitin ligase F box component, 
Fbxo3, mediates the degradation of Fbx12, thereby resulting in enhanced TRAF protein 
expression as well as increased cytokine production. Targeting Fbxo3 with highly specific 
small-molecule inhibitors resulted in increased Fbx12 expression and a subsequent reduction in 
TRAF protein levels and inflammatory cytokine production. Fbxo3 inhibitors also effectively 
lowered systemic cytokine-driven inflammation as well as the severity of colitis in vivo [199] 
(Figure 6.2). 
Feedback inhibitors such as A20 and MCIPIP1 are regulated transcriptionally by IL-17 
and other inflammatory stimuli. Therefore, identifying transcriptional repressors of the 
corresponding genes could potentially be an effective strategy to enhance A20 and MCPIP1 
expression, and subsequently, their inhibitory function. A recent report identified two 
transcription factors, DREAM and USF1, that repress A20 gene expression by binding to 
regulatory elements in the tnfaip3 promoter [200]. Therefore, drugs that inhibit DREAM or 
USF1 activity could be helpful in enhancing anti-inflammatory activity of A20. Finally, 
targeting A20 or MCPIP1 is particularly attractive as these proteins restrict multiple 
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inflammatory pathways. Based on our observations and previous reports, a therapy involving 
enhanced A20 or MCPIP1 function would simultaneously restrict IL-17, TNFα, IL-1β and LPS 
induced inflammation, thus possibly be more effective in the treatment of autoimmune 
conditions.  
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Figure 6.2: Schematic representation of targeting TRAF-mediated inflammation by using 
small molecule inhibitors. 
(A-C) This diagram represents an indirect drug targeting strategy to enhance the expression of 
TRAF inhibitory protein; Fbx12. Fbx12 targets TRAFs 1-6 to proteasome-mediated 
degradation, thus inhibiting TRAF-mediated inflammatory cytokine production. 
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6.3 CONCLUDING REMARKS 
The work presented in this thesis has improved our knowledge of the mechanisms involved in 
the inhibition of IL-17R signaling. We demonstrated that deubiquitination is an important 
mechanism involved in IL-17 signaling inhibition. In addition to A20, other DUBs such as 
CYLD and ABIN1 are known to act in TNFα and IL-1β signaling. Furthermore, MCPIP1 also 
functions as a DUB by deubiquitinating TRAFs. Therefore, it would be interesting to test 
whether additional DUBs are involved in inhibiting the IL-17 pathway. Also, additional analysis 
is required to assess the contribution of these inhibitory pathways in vivo. Given what we know 
about the involvement of IL-17 in inducing autoimmune inflammation, it is not surprising that 
there are multiple layers of inhibition in the IL-17 pathway. However, further investigation is 
required to fully grasp the interplay between these inhibitory proteins. In conclusion, feedback 
inhibition of IL-17 signaling seems to be a relevant approach in regulating this pathway and 
presents a promising opportunity to treat IL-17-mediated autoimmune conditions. 
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